WO2024126683A1

WO2024126683A1 - Coacervate core-shell microcapsules

Info

Publication number: WO2024126683A1
Application number: PCT/EP2023/085820
Authority: WO
Inventors: Jian Zhang; Christopher Hansen; Ang Li; Huda JERRI
Original assignee: Firmenich Sa
Priority date: 2022-12-14
Filing date: 2023-12-14
Publication date: 2024-06-20

Abstract

The present invention relates to plant-based coacervate core-shell microcapsules, wherein the shell comprises a Moringa oleifera extract, as well as methods and uses of the same.

Description

COACERVATE CORE-SHELL MICROCAPSULES

Technical Field

Background

Typical steps of coacervation processes generally involve (a) emulsification of a generally hydrophobic material in a solution comprising hydrocolloids, (b) coacervation (phase separation) implying the formation of a coacervate phase (c) wall formation by aggregation of the hydrocolloid around droplets of the emulsified hydrophobic material, and, (d) wallhardening, which is generally achieved by cross-linking the hydrocolloid forming the wall thus rendering the process irreversible and making the resulting microcapsules insoluble in water, resistant to mechanical stress, heat exposure and surfactant-based media.

The step of wall formation is generally driven by the surface tension difference between the coacervate phase, the water and the hydrophobic material. In most coacervation processes, one of the hydrocolloids used in coacervation processes is gelatin as it presents several advantages.

However, the use of capsules comprising gelatin is not possible in food consumer and food products wherein animal-sourced ingredients are not allowed due to regulatory, potential health hazard (mad cow disease or Bovine Spongiform Encephalopathy), cultural or religious restrictions. Moreover, it is often desirable to use plant-based ingredients compared to animal- derived ingredients for a better sustainability profile of the final consumer products, primarily due to the much more limited need for water for production of comparable amounts of proteins derived directly from plants, as compared to proteins derived from animal breeding.

Furthermore, the consumer demand for eco-friendly delivery systems is more and more important and is driving the development of new delivery systems.

Last but not least, there is an increasing consumer demand for products which contain natural extracts that provide antimicrobial benefits. Such natural products not only improve the quality of the products in which they are incorporated, but also provide consumer confidence since they are known in nature and hence not perceived as an artificial additive.

It would be therefore desirable to provide new plant-based coacervate microcapsules. Description of the Figures

Figure 1 represents optical microscope images of microcapsules A according to the invention. Figure 2 represents optical microscope images of microcapsules B according to the invention. Figure 3a and 3b represent optical microscope images of microcapsules C according to the invention.

Figure 4 represents microscope images of microcapsules according to the invention.

Figure 5 represents microscope images of microcapsules according to the invention.

Figure 6 represents scanning electron micrographs of microcapsules D according to the invention.

Figures 7 to 10 represent microscope images of microcapsules according to the invention.

Detailed description

Unless stated otherwise, percentages (%) are meant to designate a percentage by weight of a composition.

A first object of the invention is a coacervate core-shell microcapsule comprising a hydrophobic material, preferably a flavor or a perfume, wherein: a) the hydrophobic material is encapsulated in the core of the coacervate coreshell microcapsule, and b) the shell of the coacervate core-shell microcapsule comprises at least one moringa oleifera extract, and wherein the shell is cross-linked.

Another object of the invention is a coacervate core-shell microcapsule slurry comprising at least one coacervate core-shell microcapsule comprising a hydrophobic material, preferably a flavor or a perfume, wherein: a) the hydrophobic material is encapsulated in the core of the coacervate coreshell microcapsule, and b) the shell of the coacervate core-shell microcapsule comprises at least one moringa oleifera extract, and wherein the shell is cross-linked.

By “coacervate core-shell microcapsule”, it should be understood a microcapsule comprising an oily or solid-like core material (the “hydrophobic material”) surrounded by a coacervate material (also called “membrane” or “layer”). The core material can be partially or totally surrounded by the hydrogel shell.

Preferably, the coacervate core-shell microcapsules of the present invention comprises a core which is completely surrounded by a coacervate shell. According to this embodiment, it is understood that the core is completely encapsulated by a coacervate shell.

According to an embodiment, the coacervate core-shell microcapsule has a degree of cross-linking between 10 and 70 % following the method described in Soft Matter, 2011 ,7, 3315-3322 (Determination of covalent cross-linker efficacy of gelatin strands using calorimetric analyses of the gel state).

According to a particular embodiment, the coacervate core-shell microcapsules has a rupture force between 0.01 and 10 N, preferably between 0.1 and 2 N. The rupture force can be measured by compression of the capsule between parallel plates in a mechanical testing instrument, for example a Texture Analyzer (Food Technology Corporation, USA), an Instron Mechanical Testing machine (Instron, USA) or also using a rheometer device equipped with a normal force transduced (e.g. DHR-2 Rheometer manufactured by TA Instruments, USA or MCR Rheometer manufacture by Anton Paar GmbH, Germany).

The coacervate core-shell microcapsules may have a median capsule size of from 5 to 1000 pm, preferably from 5 pm to 500 pm, more preferably from 5pm to 400 pm, even more preferably from5 pm to 300 pm. The median microcapsule size of the coacervate core-shell microcapsules can be determined by standard laser diffraction particle size analysis or by light microscopy combined with image analysis. Here, for present invention, the microcapsule size refers to values based on number-based size distributions as measured by light microscopy (e.g. with a Nikon TE2000 microscope) and image analysis (performed with Nikon NIS Elements Software). Methods to obtain median and average size distributions are described in the scientific literature, e.g. R. J. Hunter, “Introduction to Modern Colloid Science”, Oxford University Press, 1994).

The coacervate core-shell microcapsules may be made by "simple" and by "complex" coacervation. By simple coacervation it is understood that the moringa oleifera extract alone is made to undergo phase separation and is then used to form a capsule wall. By complex coacervation are understood methods in which a non-protein polymer and moringa oleifera extract together form the microcapsule shell.

According to the invention, the shell of the core-shell microcapsules comprises a moringa oleifera extract. The shell can comprise mixture of plant protein extracts.

Moringa oleifera is a tree of the family Moringaceae and is native to the Indian subcontinent. The tree has been cultivated since antiquity for its beneficial food and health properties. In particular, the Moringa tree provides multifunctional benefits with leaves that are extremely nutritious (Iron, calcium, vitamin C and other micronutrients), a seed which can be pressed to yield cosmetic oil or biofuel, and additionally, a water-soluble cationic protein which has been used as an antimicrobial flocculant for water clarification for centuries. The Moringa tree is a shade-providing, nutritious tree which is vital to communities needing greater access to clean water and nutrition.

The Moringa oleifera plant contains a range of coagulation peptides (Moringa oleifera coagulation proteins (MOCP)) which bind to anionic surfaces and renders certain bacteria and microorganisms unviable. The coagulation proteins can be cationic, and such proteins can be antimicrobial because of the way they electrostatically interact with anionic biosurfaces, membranes and microorganisms. Cationic materials will also likely promote deposition and interaction with biosurfaces and fibers such as skin, hair and natural fabrics which are generally accepted to be negatively-charged, and could be used to boost the deposition performance, substantivity and tenacity of different actives.

The Moringa oleifera extract can be a Moringa oleifera seed extract or a Moringa oleifera leave extract. Preferably, it is a Moringa oleifera seed extract.

According to an embodiment, the Moringa oleifera seed extract is in an extract from Moringa oleifera seed flour, preferably de-oiled Moringa oleifera seed flour.

According to an embodiment, the Moringa oleifera seed extract comprises a Moringa oleifera protein extract.

According to the invention a “plant protein extract” or a “plant protein concentrate” is used indifferently. Typically, the content of the protein contained in the Moringa oleifera extract, preferably the Moringa oleifera seed extract (or the concentrate) is comprised between 30 and 90%, preferably between 40 and 80% percent.

According to an embodiment, the Moringa oleifera extract is present in an amount comprised between 0.1% and 30%, preferably between 1 % and 15% based on the total weight of the microcapsule.

According to an embodiment, the shell of the core-shell microcapsules also comprises a non-protein polymer or a polyelectrolyte in addition to the Moringa oleifera extract.

According to an embodiment, the shell of the core-shell microcapsules also comprises a protein polymer such as soy protein, pea protein, wheat protein, rice protein, potato protein, quinoa protein, amaranth protein, lentil protein, oat protein, buckwheat protein, chick pea protein, canola protein, lupin seeds protein and mixtures thereof, preferably the protein polymer is canola protein.

The non-protein polymer may be chosen in the group consisting of gum arabic, carboxymethylcellulose, chitosan, xanthan, agar, alginate salts, pectin, pectinate salts or carrageenan, polyallylamine hydrochloride, polystyrene sulfonate, polyethylene imine, polylysine, polyvinyl pyrrolidone, polyvinyl alcohol, preferably wherein the non-protein polymer is gum arabic or pectin, more preferably the non-protein polymer is gum arabic.

According to an embodiment, when a non-protein polymer is used, the weight ratio between the Moringa oleifera extract and the non-protein polymer is comprised between 0.1 and 10, particularly between 0.1 and 5, more particularly between 0.5 and 5, more particularly between 0.5 and 2, more particularly between 0.5 and 1 .5.

According to an embodiment, when a protein polymer is used, the weight ratio between the Moringa oleifera extract and the protein polymer is comprised between 0.1 and 10, particularly between 0.1 and 5, more particularly between 0.25 and 5, more particularly between 0.5 and 5, more particularly between 0.5 and 2, more particularly between 0.5 and 1.5.

According to an embodiment, the coacervate shell is free from animal proteins.

According to an embodiment, the coacervate shell is free from gelatin.

According to the present invention, the coacervate core-shell microcapsule comprises a hydrophobic material.

According to an embodiment, the hydrophobic material is a hydrophobic active ingredient.

By “hydrophobic active ingredient”, it is meant any hydrophobic active ingredient - single ingredient or a mixture of ingredients - which forms a two-phase dispersion when mixed with water. The hydrophobic active ingredient is preferably liquid at about 20°C.

By “active ingredient”, it is meant a single compound or a combination of ingredients.

By “perfume or flavour oil”, it is meant a single perfuming or flavouring compound or a mixture of several perfuming or flavouring compounds.

The hydrophobic material according to the invention can be “inert” material like solvents or active ingredients.

When the hydrophobic materials is an active ingredient, it is preferably chosen from the group consisting of flavors, flavor ingredients, perfumes, perfume ingredients, nutraceuticals, cosmetics, pest control agents, biocide actives and mixtures thereof.

According to a particular embodiment, the hydrophobic material comprises a mixture of a perfume with another ingredient selected from the group consisting of nutraceuticals, cosmetics, pest control agents and biocide actives.

According to an embodiment, the hydrophobic material comprises a phase change material (PCM).

According to a particular embodiment, the hydrophobic material comprises a mixture of biocide actives with another ingredient selected from the group consisting of perfumes, nutraceuticals, cosmetics, pest control agents. According to a particular embodiment, the hydrophobic material comprises a mixture of pest control agents with another ingredient selected from the group consisting of perfumes, nutraceuticals, cosmetics, biocide actives.

According to a particular embodiment, the hydrophobic material comprises a perfume. According to a particular embodiment, the hydrophobic material consists of a perfume. According to a particular embodiment, the hydrophobic material consists of biocide actives.

According to a particular embodiment, the hydrophobic material consists of pest control agents.

By “perfume” (or also “perfume oil”) what is meant here is an ingredient or a composition that is a liquid at about 20°C. According to any one of the above embodiments said perfume oil can be a perfuming ingredient alone or a mixture of ingredients in the form of a perfuming composition. As a “perfuming ingredient” it is meant here a compound, which is used for the primary purpose of conferring or modulating an odor. In other words such an ingredient, to be considered as being a perfuming one, must be recognized by a person skilled in the art as being able to at least impart or modify in a positive or pleasant way the odor of a composition, and not just as having an odor. For the purpose of the present invention, perfume oil also includes a combination of perfuming ingredients with substances which together improve, enhance or modify the delivery of the perfuming ingredients, such as perfume precursors, modulators, emulsions or dispersions, as well as combinations which impart an additional benefit beyond that of modifying or imparting an odor, such as long-lastingness, blooming, malodor counteraction, antimicrobial effect, microbial stability, pest control.

The nature and type of the perfuming ingredients present in the oil phase do not warrant a more detailed description here, which in any case would not be exhaustive, the skilled person being able to select them on the basis of its general knowledge and according to intended use or application and the desired organoleptic effect. In general terms, these perfuming ingredients belong to chemical classes as varied as alcohols, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogenous or sulfurous heterocyclic compounds and essential oils (for example Thyme oil), and said perfuming co-ingredients can be of natural or synthetic origin. Many of these co-ingredients are in any case listed in reference texts such as the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its more recent versions, or in other works of a similar nature, as well as in the abundant patent literature in the field of perfumery.

In particular one may cite perfuming ingredients which are commonly used in perfume formulations, such as: - Aldehydic ingredients: decanal, dodecanal, 2-methyl-undecanal, 10-undecenal, octanal, nonanal and/or nonenal;

- Aromatic-herbal ingredients: eucalyptus oil, camphor, eucalyptol, 5- methyltricyclo[6.2.1.0²’⁷]undecan-4-one, 1-methoxy-3-hexanethiol, 2-ethyl-4,4- dimethyl-1 ,3-oxathiane, 2,2,7/8,9/10-tetramethylspiro[5.5]undec-8-en-1-one, menthol and/or alpha-pinene;

- Balsamic ingredients: coumarin, ethylvanillin and/or vanillin;

- Citrus ingredients: dihydromyrcenol, citral, orange oil, linalyl acetate, citronellyl nitrile, orange terpenes, limonene, 1-p-menthen-8-yl acetate and/or 1,4(8)-p-menthadiene;

Floral ingredients: methyl dihydrojasmonate, linalool, citronellol, phenylethanol, 3-(4- tert-butylphenyl)-2-methylpropanal, hexylcinnamic aldehyde, benzyl acetate, benzyl salicylate, tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, beta ionone, methyl 2- (methylamino)benzoate, (E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-

2-one, (1 E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one, 1 -(2,6,6-trimethyl- 1 ,3-cyclohexadien-1-yl)-2-buten-1-one, (2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2- buten-1-one, (2E)-1-[2,6,6-trimethyl-3-cyclohexen-1-yl]-2-buten-1-one, (2E)-1 -(2,6,6- trimethyl-1-cyclohexen-1-yl)-2-buten-1-one, 3-(3,3/1,1-dimethyl-5-indanyl)propanal, 2,5-dimethyl-2-indanmethanol, 2,6,6-trimethyl-3-cyclohexene-1-carboxylate, 3-(4,4- dimethyl-1-cyclohexen-1-yl)propanal, hexyl salicylate, 3,7-dimethyl-1 ,6-nonadien-3-ol,

3-(4-isopropylphenyl)-2-methylpropanal, verdyl acetate, geraniol, p-menth-1-en-8-ol,

4-(1 ,1-dimethylethyl)-1-cyclohexyle acetate, 1,1-dimethyl-2-phenylethyl acetate, 4- cyclohexyl-2-methyl-2-butanol, amyl salicylate , high cis methyl dihydrojasmonate, 3- methyl-5-phenyl-1-pentanol, verdyl proprionate, geranyl acetate, tetrahydro linalool, cis-7-p-menthanol, propyl (S)-2-(1,1-dimethylpropoxy)propanoate, 2- methoxynaphthalene, 2, 2, 2-trichloro-1 -phenylethyl acetate, 4/3-(4-hydroxy-4- methylpentyl)-3-cyclohexene-1-carbaldehyde, amylcinnamic aldehyde, 8-decen-5- olide, 4-phenyl-2-butanone, isononyle acetate, 4-(1,1 -dimethylethyl)- 1 -cyclohexyl acetate, verdyl isobutyrate and/or mixture of methylionones isomers;

Fruity ingredients: gamma-undecalactone, 2,2,5-trimethyl-5-pentylcyclopentanone, 2- methyl-4-propyl-1 ,3-oxathiane, 4-decanolide, ethyl 2-methyl-pentanoate, hexyl acetate, ethyl 2-methylbutanoate, gamma-nonalactone, allyl heptanoate, 2- phenoxyethyl isobutyrate, ethyl 2-methyl-1 ,3-dioxolane-2-acetate, diethyl 1 ,4- cyclohexanedicarboxylate, 3-methyl-2-hexen-1-yl acetate, 1-[3,3- dimethylcyclohexyl]ethyl [3-ethyl-2-oxiranyl]acetate and/or diethyl 1 ,4-cyclohexane dicarboxylate; Green ingredients: 2-methyl-3-hexanone (E)-oxime, 2,4-dimethyl-3-cyclohexene-1- carbaldehyde, 2-tert- butyl- 1 -cyclohexyl acetate, styrallyl acetate, allyl (2- methylbutoxy)acetate, 4-methyl-3-decen-5-ol, diphenyl ether, (Z)-3-hexen-1-ol and/or 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one;

Musk ingredients: 1 ,4-dioxa-5,17-cycloheptadecanedione, (Z)-4-cyclopentadecen-1- one, 3-methylcyclopentadecanone, 1-oxa-12-cyclohexadecen-2-one, 1-oxa-13- cyclohexadecen-2-one, (9Z)-9-cycloheptadecen-1-one, 2-{(1S)-1-[(1 R)-3,3- dimethylcyclohexyl]ethoxy}-2-oxoethyl propionate, 3-methyl-5-cyclopentadecen-1- one, 4,6,6,7,8,8-hexamethyl-1 ,3,4,6,7,8-hexahydrocyclopenta[g]isochromene, (1S,1'R)-2-[1-(3',3'-dimethyl-T-cyclohexyl)ethoxy]-2-methylpropyl propanoate, oxacyclohexadecan-2-one and/or (1S,TR)-[1-(3',3'-dimethyl-T- cyclohexyl)ethoxycarbonyl]methyl propanoate;

- Woody ingredients: 1-[(1 RS,6SR)-2,2,6-trimethylcyclohexyl]-3-hexanol, 3,3-dimethyl- 5-[(1 R)-2,2,3-trimethyl-3-cyclopenten-1-yl]-4-penten-2-ol, 3,4'-dimethylspiro[oxirane- 2,9'-tricyclo[6.2.1.0²’⁷]undec[4]ene, (l-ethoxyethoxy)cyclododecane, 2,2,9, 11 - tetramethylspiro[5.5]undec-8-en-1-yl acetate, 1 -(octahydro-2, 3,8, 8-tetramethyl-2- naphtalenyl)-1 -ethanone, patchouli oil, terpenes fractions of patchouli oil, Clearwood®, (TR,E)-2-ethyl-4-(2',2',3'-trimethyl-3'-cyclopenten-T-yl)-2-buten-1-ol, 2-ethyl-4- (2,2,3- trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, methyl cedryl ketone, 5-(2,2,3-trimethyl-3- cyclopentenyl)-3-methylpentan-2-ol, 1-(2,3,8,8-tetramethyl-1 ,2,3,4,6,7,8,8a- octahydronaphthalen-2-yl)ethan-1-one and/or isobornyl acetate;

Other ingredients (e.g. amber, powdery spicy or watery): dodecahydro-3a,6,6,9a- tetramethyl-naphtho[2,1-b]furan and any of its stereoisomers, heliotropin, anisic aldehyde, eugenol, cinnamic aldehyde, clove oil, 3-(1 ,3-benzodioxol-5-yl)-2- methylpropanal, 7-methyl-2H-1 ,5-benzodioxepin-3(4H)-one, 2,5,5-trimethyl- 1 ,2,3,4,4a,5,6,7-octahydro-2-naphthalenol, 1-phenylvinyl acetate, 6-methyl-7-oxa-1- thia-4-azaspiro[4.4]nonane and/or 3-(3-isopropyl-1-phenyl)butanal.

It is also understood that said ingredients may also be compounds known to release in a controlled manner various types of perfuming compounds also known as properfume or profragrance. Non-limiting examples of suitable properfumes may include 4-(dodecylthio)- 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-butanone, 4-(dodecylthio)-4-(2,6,6-trimethyl-1- cyclohexen-1-yl)-2-butanone, 3-(dodecylthio)-1-(2,6,6-trimethyl-3-cyclohexen-1-yl)-1- butanone, 2-(dodecylthio)octan-4-one, 2-phenylethyl oxo(phenyl)acetate, 3,7- dimethylocta-2,6-dien-1-yl oxo(phenyl)acetate, (Z)-hex-3-en-1-yl oxo(phenyl)acetate, 3,7- dimethyl-2,6-octadien-1-yl hexadecanoate, bis(3,7-dimethylocta-2,6-dien-1-yl) succinate, (2-((2-methylundec-1-en-1-yl)oxy)ethyl)benzene, 1-methoxy-4-(3-methyl-4- phenethoxybut-3-en- 1 -yl) benzene, (3-methyl-4-phenethoxybut-3-en- 1 -yl) benzene, 1 - (((Z)-hex-3-en-1-yl)oxy)-2-methylundec-1-ene, (2-((2-methylundec-1-en-1- yl)oxy)ethoxy)benzene, 2-methyl-1-(octan-3-yloxy)undec-1-ene, 1-methoxy-4-(1- phenethoxyprop-1-en-2-yl)benzene, 1-methyl-4-(1 -phenethoxyprop-1 -en-2-yl)benzene, 2- (1 -phenethoxyprop-1 -en-2-yl)naphthalene, (2-phenethoxyvinyl)benzene, 2-(1 -((3,7- dimethyloct-6-en-1-yl)oxy)prop-1-en-2-yl)naphthalene, (2-((2- pentylcyclopentylidene)methoxy)ethyl)benzene, 4-allyl-2-methoxy-1-((2-methoxy-2- phenylvinyl)oxy)benzene, (2-((2-heptylcyclopentylidene)methoxy)ethyl)benzene, 1- isopropyl-4-methyl-2-((2-pentylcyclopentylidene)methoxy)benzene, 2-methoxy-1-((2- pentylcyclopentylidene)methoxy)-4-propylbenzene, 3-methoxy-4-((2-methoxy-2- phenylvinyl)oxy)benzaldehyde, 4-((2-(hexyloxy)-2-phenylvinyl)oxy)-3- methoxybenzaldehyde or a mixture thereof.

The perfuming ingredients may be dissolved in a solvent of current use in the perfume industry. The solvent is preferably not an alcohol. Examples of such solvents are diethyl phthalate, isopropyl myristate, Abalyn® (rosin resins, available from Eastman), benzyl benzoate, ethyl citrate, triethyl citrate, limonene or other terpenes, or isoparaffins. Preferably, the solvent is very hydrophobic and highly sterically hindered, like for example Abalyn® or benzyl benzoate. Preferably the perfume comprises less than 30% of solvent. More preferably the perfume comprises less than 20% and even more preferably less than 10% of solvent, all these percentages being defined by weight relative to the total weight of the perfume. Most preferably, the perfume is essentially free of solvent.

Preferred perfuming ingredients are those having a high steric hindrance (bulky materials) and in particular those from one of the following groups:

Group 1 : perfuming ingredients comprising a cyclohexane, cyclohexene, cyclohexanone or cyclohexenone ring substituted with at least one linear or branched Ci to C4 alkyl or alkenyl substituent;

Group 2: perfuming ingredients comprising a cyclopentane, cyclopentene, cyclopentanone or cyclopentenone ring substituted with at least one linear or branched C4 to Cs alkyl or alkenyl substituent;

Group 3: perfuming ingredients comprising a phenyl ring or perfuming ingredients comprising a cyclohexane, cyclohexene, cyclohexanone or cyclohexenone ring substituted with at least one linear or branched C5 to Cs alkyl or alkenyl substituent or with at least one phenyl substituent and optionally one or more linear or branched Ci to C3 alkyl or alkenyl substituents;

Group 4: perfuming ingredients comprising at least two fused or linked C5 and/or Cs rings; Group 5: perfuming ingredients comprising a camphor-like ring structure; Group 6: perfuming ingredients comprising at least one C7 to C20 ring structure;

Group 7: perfuming ingredients having a logP value above 3.5 and comprising at least one tert-butyl or at least one trichloromethyl substitutent;

Examples of ingredients from each of these groups are:

Group 1 : 2,4-dimethyl-3-cyclohexene-1-carbaldehyde (origin: Firmenich SA, Geneva, Switzerland), isocyclocitral, menthone, isomenthone, methyl 2, 2-dimethyl-6-methylene-1- cyclohexanecarboxylate (origin: Firmenich SA, Geneva, Switzerland), nerone, terpineol, dihydroterpineol, terpenyl acetate, dihydroterpenyl acetate, dipentene, eucalyptol, hexylate, rose oxide, (S)-1 ,8-p-menthadiene-7-ol (origin: Firmenich SA, Geneva, Switzerland), 1-p-menthene-4-ol, (1 RS,3RS,4SR)-3-p-mentanyl acetate, (1 R,2S,4R)- 4,6,6-trimethyl-bicyclo[3,1 ,1]heptan-2-ol, tetrahydro-4-methyl-2-phenyl-2H-pyran (origin: Firmenich SA, Geneva, Switzerland), cyclohexyl acetate, cyclanol acetate, 1 ,4- cyclohexane diethyldicarboxylate (origin: Firmenich SA, Geneva, Switzerland), (3RS,3aRS,6SR,7ASR)-perhydro-3,6-dimethyl-benzo[B]furan-2-one (origin: Firmenich SA, Geneva, Switzerland), ((6R)-perhydro-3,6-dimethyl-benzo[B]furan-2-one (origin: Firmenich SA, Geneva, Switzerland), 2,4,6-trimethyl-4-phenyl-1 ,3-dioxane, 2,4,6- trimethyl-3-cyclohexene-1-carbaldehyde;

Group 2: (E)-3-methyl-5-(2,2,3-trimethyl-3-cyclopenten-1-yl)-4-penten-2-ol (origin: Givaudan SA, Vernier, Switzerland), (TR,E)-2-ethyl-4-(2',2',3'-trimethyl-3'-cyclopenten-T- yl)-2-buten-1-ol (origin: Firmenich SA, Geneva, Switzerland), (1'R,E)-3,3-dimethyl-5- (2',2',3'-trimethyl-3'-cyclopenten-T-yl)-4-penten-2-ol (origin: Firmenich SA, Geneva, Switzerland), 2-heptylcyclopentanone, methyl-cis-3-oxo-2-pentyl-1 -cyclopentane acetate (origin: Firmenich SA, Geneva, Switzerland), 2,2,5-trimethyl-5-pentyl-1-cyclopentanone (origin: Firmenich SA, Geneva, Switzerland), 3,3-dimethyl-5-(2,2,3-trimethyl-3- cyclopenten-1-yl)-4-penten-2-ol (origin: Firmenich SA, Geneva, Switzerland), 3-methyl-5- (2,2,3-trimethyl-3-cyclopenten-1-yl)-2-pentanol (origin, Givaudan SA, Vernier, Switzerland);

Group 3: damascenes, 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one (origin: Firmenich SA, Geneva, Switzerland), (1'R)-2-[2-(4'-methyl-3'-cyclohexen-T- yl)propyl]cyclopentanone, alpha-ionone, beta-ionone, damascenone, mixture of 1-(5,5- dimethyl- 1 -cyclohexen-1 -yl)-4-penten- 1 -one and 1 -(3,3-dimethyl- 1 -cyclohexen- 1 -yl)-4- penten-1-one (origin: Firmenich SA, Geneva, Switzerland), 1-(2,6,6-trimethyl-1- cyclohexen-1-yl)-2-buten-1-one (origin: Firmenich SA, Geneva, Switzerland), (1S,1'R)-[1- (3',3'-Dimethyl-T-cyclohexyl)ethoxycarbonyl]methyl propanoate (origin: Firmenich SA, Geneva, Switzerland), 2-tert-butyl-1 -cyclohexyl acetate (origin: International Flavors and Fragrances, USA), 1-(2,2,3,6-tetramethyl-cyclohexyl)-3-hexanol (origin: Firmenich SA, Geneva, Switzerland), trans-1-(2,2,6-trimethyl-1-cyclohexyl)-3-hexanol (origin: Firmenich SA, Geneva, Switzerland), (E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2- one, terpenyl isobutyrate, 4-(1 ,1-dimethylethyl)-1-cyclohexyl acetate (origin: Firmenich SA, Geneva, Switzerland), 8-methoxy-1-p-menthene, (1S,1'R)-2-[1-(3',3'-dimethyl-T- cyclohexyl) ethoxy]-2-methylpropyl propanoate (origin: Firmenich SA, Geneva, Switzerland), para tert-butylcyclohexanone, menthenethiol, 1-methyl-4-(4-methyl-3- pentenyl)-3-cyclohexene-1-carbaldehyde, allyl cyclohexylpropionate, cyclohexyl salicylate, 2-methoxy-4-methylphenyl methyl carbonate, ethyl 2-methoxy-4-methylphenyl carbonate, 4-ethyl-2-methoxyphenyl methyl carbonate;

Group 4: Methyl cedryl ketone (origin: International Flavors and Fragrances, USA), a mixture of (1 RS,2SR,6RS,7RS,8SR)-tricyclo[5.2.1.0²’⁶]dec-3-en-8-yl 2-methylpropanoate and (1 RS,2SR,6RS,7RS,8SR)-tricyclo[5.2.1 ,0²’⁶]dec-4-en-8-yl 2-methylpropanoate, vetyverol, vetyverone, 1 -(octahydro-2, 3, 8, 8-tetramethyl-2-naphtalenyl)-1 -ethanone (origin: International Flavors and Fragrances, USA), (5RS,9RS,10SR)-2,6,9, 10- tetramethyl-1-oxaspiro[4.5]deca-3,6-diene and the (5RS,9SR,10RS) isomer, 6-ethyl- 2,10,10-trimethyl-1-oxaspiro[4.5]deca-3,6-diene, 1 ,2,3,5,6,7-hexahydro-1 ,1 ,2,3,3- pentamethyl-4-indenone (origin: International Flavors and Fragrances, USA), a mixture of 3-(3,3-dimethyl-5-indanyl)propanal and 3-(1 ,1-dimethyl-5-indanyl)propanal (origin: Firmenich SA, Geneva, Switzerland), 3',4-dimethyl-tricyclo[6.2.1.0(2,7)]undec-4-ene-9- spiro-2'-oxirane (origin: Firmenich SA, Geneva, Switzerland), 9/10-ethyldiene-3- oxatricyclo[6.2.1 ,0(2,7)]undecane, (perhydro-5,5,8A-trimethyl-2-naphthalenyl acetate (origin: Firmenich SA, Geneva, Switzerland), octalynol, (dodecahydro-3a,6,6,9a- tetramethyl-naphtho[2,1-b]furan, origin: Firmenich SA, Geneva, Switzerland), tricyclo[5.2.1.0(2,6)]dec-3-en-8-yl acetate and tricyclo[5.2.1.0(2,6)]dec-4-en-8-yl acetate as well as tricyclo[5.2.1.0(2,6)]dec-3-en-8-yl propanoate and tricyclo[5.2.1.0(2,6)]dec-4- en-8-yl propanoate, (+)-(1S,2S,3S)-2,6,6-trimethyl-bicyclo[3.1.1]heptane-3-spiro-2'- cyclohexen-4'-one;

Group 5: camphor, borneol, isobornyl acetate, 8-isopropyl-6-methyl-bicyclo[2.2.2]oct-5- ene-2-carbaldehyde, pinene, camphene, 8-methoxycedrane, (8- meth oxy-2, 6, 6, 8- tetramethyl-tricyclo[5.3.1.0(1 ,5)]undecane (origin: Firmenich SA, Geneva, Switzerland), cedrene, cedrenol, cedrol, mixture of 9-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4- one and 10-ethylidene-3-oxatricyclo[6.2.1.0²’⁷]undecan-4-one (origin: Firmenich SA, Geneva, Switzerland), 3-methoxy-7,7-dimethyl-10-methylene-bicyclo[4.3.1]decane (origin: Firmenich SA, Geneva, Switzerland);

Group 6: (trimethyl-13-oxabicyclo-[10.1.0]-trideca-4,8-diene (origin: Firmenich SA, Geneva, Switzerland), 9-hexadecen- 16-olide (origin: Firmenich SA, Geneva, Switzerland), pentadecenolide (origin: Firmenich SA, Geneva, Switzerland), 3-methyl-(4/5)- cyclopentadecenone .(origin: Firmenich SA, Geneva, Switzerland), 3- methylcyclopentadecanone (origin: Firmenich SA, Geneva, Switzerland), pentadecanolide (origin: Firmenich SA, Geneva, Switzerland), cyclopentadecanone (origin: Firmenich SA, Geneva, Switzerland), 1-ethoxyethoxy)cyclododecane (origin: Firmenich SA, Geneva, Switzerland), 1 ,4-dioxacycloheptadecane-5, 17-dione, 4,8-cyclododecadien-1-one;

Group 7: (+-)-2-methyl-3-[4-(2-methyl-2-propanyl)phenyl]propanal (origin: Givaudan SA, Vernier, Switzerland), 2,2,2-trichloro-1-phenylethyl acetate.

Preferably, the perfume comprises at least 30%, preferably at least 50%, more preferably at least 60% of ingredients selected from Groups 1 to 7, as defined above. More preferably said perfume comprises at least 30%, preferably at least 50% of ingredients from Groups 3 to 7, as defined above. Most preferably said perfume comprises at least 30%, preferably at least 50% of ingredients from Groups 3, 4, 6 or 7, as defined above.

According to another preferred embodiment, the perfume comprises at least 30%, preferably at least 50%, more preferably at least 60% of ingredients having a logP above 3, preferably above 3.5 and even more preferably above 3.75.

According to a particular embodiment, the perfume used in the invention contains less than 10% of its own weight of primary alcohols, less than 15% of its own weight of secondary alcohols and less than 20% of its own weight of tertiary alcohols. Advantageously, the perfume used in the invention does not contain any primary alcohols and contains less than 15% of secondary and tertiary alcohols.

According to an embodiment, the oil phase (or the oil-based core) comprises: 25-100wt%, preferably 25-98% of a perfume oil comprising at least 15wt% of high impact perfume raw materials having a Log T<-4, and

0-75wt%, preferably 2-75% of a density balancing material having a density greater than 1.07 g/cm³.

“High impact perfume raw materials" should be understood as perfume raw materials having a LogT<-4. The odor threshold concentration of a chemical compound is determined in part by its shape, polarity, partial charges and molecular mass. For convenience, the odor threshold concentration is presented as the common logarithm of the threshold concentration, i.e., Log [Threshold] (“LogT”).

A “density balancing material" should be understood as a material having a density greater than 1.07 g/cm³ and having preferably low or no odor.

The odor threshold concentration of a perfuming compound is determined by using a gas chromatograph (“GC”). Specifically, the gas chromatograph is calibrated to determine the exact volume of the perfume oil ingredient injected by the syringe, the precise split ratio, and the hydrocarbon response using a hydrocarbon standard of known concentration and chainlength distribution. The air flow rate is accurately measured and, assuming the duration of a human inhalation to last 12 seconds, the sampled volume is calculated. Since the precise concentration at the detector at any point in time is known, the mass per volume inhaled is known and hence the concentration of the perfuming compound. To determine the threshold concentration, solutions are delivered to the sniff port at the back-calculated concentration. A panelist sniffs the GC effluent and identifies the retention time when odor is noticed. The average across all panelists determines the odor threshold concentration of the perfuming compound. The determination of odor threshold is described in more detail in C. Vuilleumier et al., Multidimensional Visualization of Physical and Perceptual Data Leading to a Creative Approach in Fragrance Development, Perfume & Flavorist, Vol. 33, September, 2008, pages 54-61 .

The nature of high impact perfume raw materials having a Log T<-4 and density balancing material having a density greater than 1.07 g/cm³ are described in WO2018115250, the content of which are included by reference.

According to an embodiment, the high impact perfume raw materials having a Log T<-4 are selected from the group consisting of (+-)-1-methoxy-3-hexanethiol, 4-(4-hydroxy-1-phenyl)- 2-butanone, 2-methoxy-4-(1 -propenyl)- 1 -phenyl acetate, pyrazobutyle, 3-propylphenol, 1-(3- methyl-1-benzofuran-2-yl)ethanone, 2-(3-phenylpropyl)pyridine, 1-(3,3/5,5-dimethyl-1- cyclohexen-1-yl)-4-penten-1-one , 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one, a mixture comprising (3RS,3aRS,6SR,7ASR)-perhydro-3,6-dimethyl-benzo[b]furan-2-one and (3SR,3aRS,6SR,7ASR)-perhydro-3,6-dimethyl-benzo[b]furan-2-one, (+-)-1-(5-ethyl-5- methyl-1-cyclohexen-1-yl)-4-penten-1-one, (TS,3'R)-1-methyl-2-[(1',2',2'- trimethylbicyclo[3.1 .0]hex-3'-yl)methyl]cyclopropyl}methanol, (+-)-3-mercaptohexyl acetate, (2E)-1-(2,6,6-trimethyl-1 ,3-cyclohexadien-1-yl)-2-buten-1-one, H-methyl-2h-1 ,5- benzodioxepin-3(4H)-one, (2E,6Z)-2,6-nonadien-1-ol, (4Z)-4-dodecenal, (+-)-4-hydroxy-2,5- dimethyl-3(2H)-furanone, methyl 2,4-dihydroxy-3,6-dimethylbenzoate, 3-methylindole, (+-)- perhydro-4alpha,8abeta-dimethyl-4a-naphthalenol, patchoulol, 2-methoxy-4-(1- propenyl)phenol, mixture comprising (+-)-5,6-dihydro-4-methyl-2-phenyl-2H-pyran and tetrahydro-4-methylene-2-phenyl-2H-pyran, mixture comprising 4-methylene-2- phenyltetrahydro-2H-pyran and (+-)-4-methyl-2-phenyl-3,6-dihydro-2H-pyran, 4-hydroxy-3- methoxybenzaldehyde, nonylenic aldehyde, 2-methoxy-4-propylphenol, 3-methyl-5-phenyl-2- pentenenitrile, 1-(spiro[4.5]dec-6/7-en-7-yl)-4-penten-1-one(, 2-methoxynaphthalene, (-)- (3aR,5AS,9AS,9BR)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, 5-nonanolide, (3aR,5AS,9AS,9BR)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, 7-isopropyl- 2H,4H-1 ,5-benzodioxepin-3-one, coumarin, 4-methylphenyl isobutyrate, (2E)-1-(2,6,6- trimethyl-1 ,3-cyclohexadien-1-yl)-2-buten-1-one, beta, 2,2, 3-tetramethyl-delta-methylene-3- cyclopentene-1-butanol, delta damascene ((2E)-1-[(1 RS,2SR)-2,6,6-trimethyl-3-cyclohexen-

1-yl]-2-buten-1-one), (+-)-3,6-dihydro-4,6-dimethyl-2-phenyl-2h-pyran, anisaldehyde, paracresol, 3-ethoxy-4-hydroxybenzaldehyde, methyl 2-aminobenzoate, ethyl methylphenylglycidate, octalactone gamma, ethyl 3-phenyl-2-propenoate, (-)-(2E)-2-ethyl-4- [(1 R)-2,2,3-trimethyl-3-cyclopenten-1-yl]-2-buten-1-ol, paracresyl acetate, dodecalactone, tricyclone, (+)-(3R,5Z)-3-methyl-5-cyclopentadecen-1-one, undecalactone, (1 R,4R)-8- mercapto-3-p-menthanone, (3S,3AS,6R,7AR)-3,6-dimethylhexahydro-1-benzofuran-2(3H)- one, beta ionone, (+-)-6-pentyltetrahydro-2H-pyran-2-one, (3E,5Z)-1 ,3,5-undecatriene, 10- undecenal, (9E)-9-undecenal (9Z)-9-undecenal, (Z)-4-decenal, (+- )-ethyl 2- methylpentanoate, 1 ,2-diallyldisulfane, 2-tridecenenitrile, 3-tridecenenitrile, , (+-)-2-ethyl-4,4- dimethyl-1 ,3-oxathiane, (+)-(3R,5Z)-3-methyl-5-cyclopentadecen-1-one, 3-(4-tert- butylphenyl)propanal, allyl (cyclohexyloxy)acetate, methylnaphthylketone, (+-)-(4E)-3-methyl- 4-cyclopentadecen-1-one, (+-)-5E3-methyl-5-cyclopentadecen-1-one, cyclopropyl methyl 3- hexenoate, (4E)-4-methyl-5-(4-methylphenyl)-4-pentenal, (+-)-1-(5-propyl-1 ,3-benzodioxol-2- yl)ethanone, 4-methyl-2-pentylpyridine, (+-)-(E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1- yl)-3-buten-2-one, (3aRS,5aSR,9aSR,9bRS)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1- b]furan, (2S,5R)-5-methyl-2-(2-propanyl)cyclohexanone oxime, 6-hexyltetrahydro-2H-pyran-

2-one, (+-)-3-(3-isopropyl-1-phenyl)butanal, methyl 2-(3-oxo-2-pentylcyclopentyl)acetate, 1-

(2,6,6-trimethyl-1-cyclohex-2-enyl)pent-1-en-3-one, indol, 7-propyl-2H,4H-1 ,5- benzodioxepin-3-one, ethyl praline, (4-methylphenoxy)acetaldehyde, ethyl tricyclo[5.2.1.0.²’⁶]decane-2-carboxylate, (+)-(TS,2S,E)-3,3-dimethyl-5-(2',2',3'-trimethyl-3'- cyclopenten-1'-yl)-4-penten-2-ol, (4E)-3,3-dimethyl-5-[(1 R)-2,2,3-trimethyl-3-cyclopenten-1- yl]-4-penten-2-ol, 8-isopropyl-6-methyl-bicyclo[2.2.2]oct-5-ene-2-carbaldehyde, methylnonylacetaldehyde, 4-formyl-2-methoxyphenyl 2-methylpropanoate, (E)-4-decenal, (+- )-2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, (1 R,5R)-4,7,7-trimethyl-6- thiabicyclo[3.2.1]oct-3-ene, (1 R,4R,5R)-4,7,7-trimethyl-6-thiabicyclo[3.2.1]octane, (-)-(3R)- 3,7-dimethyl-1 ,6-octadien-3-ol, (E)-3-phenyl-2-propenenitrile, 4-methoxybenzyl acetate, (E)-

3-methyl-5-(2,2,3-trimethyl-3-cyclopenten-1-yl)-4-penten-2-ol, allyl (2/3- methylbutoxy)acetate, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, (1 E)-1- (2,6,6-trimethyl-1-cyclohexen-1-yl)-1-penten-3-one, and mixtures thereof.

According to an embodiment, perfume raw materials having a Log T<-4 are chosen in the group consisting of aldehydes, ketones, alcohols, phenols, esters lactones, ethers, epoxydes, nitriles and mixtures thereof. According to an embodiment, perfume raw materials having a Log T<-4 comprise at least one compound chosen in the group consisting of alcohols, phenols, esters lactones, ethers, epoxydes, nitriles and mixtures thereof, preferably in amount comprised between 20 and 70% by weight based on the total weight of the perfume raw materials having a Log T<-4.

According to an embodiment, perfume raw materials having a Log T<-4 comprise between 20 and 70% by weight of aldehydes, ketones, and mixtures thereof based on the total weight of the perfume raw materials having a Log T<-4.

The remaining perfume raw materials contained in the oil-based core may have therefore a Log T>-4.

According to an embodiment, the perfume raw materials having a Log T>-4 are chosen in the group consisting of ethyl 2-methylbutyrate, (E)-3-phenyl-2-propenyl acetate, (+-)-6/8-sec- butylquinoline, (+-)-3-(1 ,3-benzodioxol-5-yl)-2-methylpropanal, verdyl propionate, 1- (octahydro-2, 3, 8, 8-tetramethyl-2-naphtalenyl)-1 -ethanone, methyl 2-((1 RS,2RS)-3-oxo-2- pentylcyclopentyl)acetate, (+-)-(E)-4-methyl-3-decen-5-ol, 2,4-dimethyl-3-cyclohexene-1- carbaldehyde, 1 ,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, tetrahydro-4-methyl-2-(2-methyl-1- propenyl)-2H-pyran, dodecanal, 1-oxa-12/13-cyclohexadecen-2-one, (+-)-3-(4- isopropylphenyl)-2-methylpropanal, aldehyde C11 , (+-)-2,6-dimethyl-7-octen-2-ol, allyl 3- cyclohexylpropanoate, (Z)-3-hexenyl acetate, 5-methyl-2-(2-propanyl)cyclohexanone, allyl heptanoate, 2-(2-methyl-2-propanyl)cyclohexyl acetate, 1 ,1-dimethyl-2-phenylethyl butyrate, geranyl acetate, neryl acetate, (+-)-1 -phenylethyl acetate, 1 ,1-dimethyl-2-phenylethyl acetate, 3-methyl-2-butenyl acetate, ethyl 3-oxobutanoate, (2Z)-ethyl 3-hydroxy-2-butenoate, 8-p- menthanol, 8-p-menthanyl acetate, 1-p-menthanyl acetate, (+-)-2-(4-methyl-3-cyclohexen-1- yl)-2-propanyl acetate, (+-)-2-methyl butyl butanoate, 2-{(1S)-1-[(1 R)-3,3- dimethylcyclohexyl]ethoxy}-2-oxoethyl propionate, 3,5,6-trimethyl-3-cyclohexene-1- carbaldehyde, 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde, 2-cyclohexylethyl acetate, octanal, ethyl butanoate, (+-)-(3E)-4-(2,6,6-trimethyl-1/2-cyclohexen-1-yl)-3-buten-2-one, 1- [(1 RS,6SR)-2,2,6-trimethylcyclohexyl]-3-hexanol, 1 ,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 1 ,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, ethyl hexanoate, undecanal, decanal, 2-phenylethyl acetate, (1 S,2S,4S)-1 ,7,7-trimethylbicyclo[2.2.1]heptan-2-ol, (1 S,2R,4S)-1 ,7,7- trimethylbicyclo[2.2.1]heptan-2-ol ), (+-)-3,7-dimethyl-3-octanol, 1-methyl-4-(2- propanylidene)cyclohexene, (+)-(R)-4-(2-methoxypropan-2-yl)-1 -methylcyclohex- 1 -ene, verdyl acetate, (3R)-1-[(1 R,6S)-2,2,6-trimethylcyclohexyl]-3-hexanol, (3S)-1-[(1 R,6S)-2,2,6- trimethylcyclohexyl]-3-hexanol, (3R)-1-[(1S,6S)-2,2,6-trimethylcyclohexyl]-3-hexanol, (+)- (1S,TR)-2-[1-(3',3'-dimethyl-T-cyclohexyl)ethoxy]-2-methylpropyl propanoate, and mixtures thereof.

According to an embodiment, the perfume formulation comprises 0 to 60 wt.% of a hydrophobic solvent (based on the total weight of the perfume formulation),

40 to 100 wt.% of a perfume oil (based on the total weight of the perfume formulation), wherein the perfume oil has at least two, preferably all of the following characteristics: o at least 35%, preferably at least 40%, preferably at least 50%, more preferably at least 60% of perfuming ingredients having a log P above 3, preferably above 3.5, o at least 20%, preferably at least 25%, preferably at least 30%, more preferably at least 40% of Bulky materials of groups 1 to 6, preferably 3 to 6 as defined previously and o at least 15%, preferably at least 20%, more preferably at least 25%, even more preferably at least 30% of high impact perfume materials having a Log T < -4 as defined previously, optionally, further hydrophobic active ingredients.

According to a particular embodiment, the perfume comprises 0 to 60 wt.% of a hydrophobic solvent.

According to a particular embodiment, the hydrophobic solvent is a density balancing material preferably chosen in the group consisting of benzyl salicylate, benzyl benzoate, cyclohexyl salicylate, benzyl phenylacetate, phenylethyl phenylacetate, triacetin, ethyl citrate, methyl and ethyl salicylate, benzyl cinnamate, and mixtures thereof.

In a particular embodiment, the hydrophobic solvent has Hansen Solubility Parameters compatible with entrapped perfume oil.

The term "Hansen solubility parameter" is understood refers to a solubility parameter approach proposed by Charles Hansen used to predict polymer solubility and was developed around the basis that the total energy of vaporization of a liquid consists of several individual parts. To calculate the "weighted Hansen solubility parameter" one must combine the effects of (atomic) dispersion forces, (molecular) permanent dipole-permanent dipole forces, and (molecular) hydrogen bonding (electron exchange). The weighted Hansen solubility parameter" is calculated as (5D²+ 5P²+ 5H²)⁰⁵, wherein <5D is the Hansen dispersion value (also referred to in the following as the atomic dispersion fore), <5P is the Hansen polarizability value (also referred to in the following as the dipole moment), and <5H is the Hansen Hydrogenbonding ("h-bonding") value (also referred to in the following as hydrogen bonding). For a more detailed description of the parameters and values, see Charles Hansen, The Three Dimensional Solubility Parameter and Solvent Diffusion Coefficient, Danish Technical Press (Copenhagen, 1967). Euclidean difference in solubility parameter between a fragrance and a solvent is calculated aS (4*(5Dsolvenf6Dfragrance)2 + (bP solvenfQPfragrance)^ + (bHsolvent-bHfragrance)^ )^{0 5}, in which bD_SOivent, GPsoivent, and SHsoivent, are the Hansen dispersion value, Hansen polarizability value, and Hansen h-bonding values of the solvent, respectively; and bDf_ragrance, GPfrag rance, and bHfragrance are the Hansen dispersion value, Hansen polarizability value, and Hansen h-bonding values of the fragrance, respectively.

In a particular embodiment, the perfume oil and the hydrophobic solvent have at least two Hansen solubility parameters selected from a first group consisting of: an atomic dispersion force (bD) from 12 to 20, a dipole moment (bP) from 1 to 8, and a hydrogen bonding (bH) from 2.5 to 11.

In a particular embodiment, the perfume oil and the hydrophobic solvent have at least two Hansen solubility parameters selected from a second group consisting of: an atomic dispersion force (bD) from 12 to 20, preferably from 14 to 20, a dipole moment (bP) from 1 to 8, preferably from 1 to 7, and a hydrogen bonding (bH) from 2.5 to 11 , preferably from 4 to 11.

In a particular embodiment, at least 90% of the perfume oil, preferably at least 95% of the perfume oil, most preferably at least of 98% of the perfume oil has at least two Hansen solubility parameters selected from a first group consisting of: an atomic dispersion force (bD) from 12 to 20, a dipole moment (bP) from 1 to 8, and a hydrogen bonding (bH) from 2.5 to 11.

According to an embodiment, the perfuming formulation comprises a fragrance modulator (that can be used in addition to the hydrophobic solvent when present or as substitution of the hydrophobic solvent when there is no hydrophobic solvent).

Preferably, the fragrance modulator is defined as a fragrance material with i. a vapor pressure of less than 0.0008 Torr at 22°C; ii. a clogP of 3.5 and higher, preferably 4.0 and higher and more preferably 4.5 iii. at least two Hansen solubility parameters selected from a first group consisting of: an atomic dispersion force from 12 to 20, a dipole moment from 1 to 7, and a hydrogen bonding from 2.5 to 11 , iv. at least two Hansen solubility parameters selected from a second group consisting of: an atomic dispersion force from 14 to 20, a dipole moment from 1 to 8, and a hydrogen bonding from 4 to 11, when in solution with a compound having a vapor pressure range of 0.0008 to 0.08 Torr at 22°C. Preferably, as examples the following ingredients can be listed as modulators but the list in not limited to the following materials: alcohol C12, oxacyclohexadec- 12/13-en-2-one, 3- [(2',2',3'-trimethyl-3'-cyclopenten-T-yl)methoxy]-2-butanol, cyclohexadecanone, (Z)-4- cyclopentadecen-1-one, cyclopentadecanone, (8Z)-oxacycloheptadec-8-en-2-one, 2-[5- (tetrahydro-5-methyl-5-vinyl-2-furyl)-tetrahydro-5-methyl-2-furyl]-2-propanol, muguet aldehyde, 1 ,5,8-trimethyl-13-oxabicyclo[10.1 ,0]trideca-4,8-diene, (+- )-4 ,6 ,6 , 7, 8, 8- hexamethyl-1 ,3,4,6,7,8-hexahydrocyclopenta[g]isochromene, (+)-(1S,2S,3S,5R)-2,6,6- trimethylspiro[bicyclo[3.1.1]heptane-3,T-cyclohexane]-2'-en-4'-one, oxacyclohexadecan-2- one, 2-{(1S)-1-[(1 R)-3,3-dimethylcyclohexyl]ethoxy}-2-oxoethyl propionate, (+)-(4R,4aS,6R)- 4,4a-dimethyl-6-(1-propen-2-yl)-4,4a,5,6,7,8-hexahydro-2(3H)-naphthalenone, amylcinnamic aldehyde, hexylcinnamic aldehyde, hexyl salicylate, (1 E)-1-(2,6,6-trimethyl-1-cyclohexen-1- yl)-1 ,6-heptadien-3-one, (9Z)-9-cycloheptadecen-1-one.

According to a particular embodiment, the hydrophobic material is free of any active ingredient (such as perfume). According to this particular embodiment, it comprises, preferably consists of hydrophobic solvents, preferably chosen in the group consisting of isopropyl myristate, tryglycerides (e.g. Neobee® MCT oil, vegetable oils), D-limonene, silicone oil, mineral oil, and mixtures thereof with optionally hydrophilic solvents preferably chosen in the group consisting of 1 ,4-butanediol, benzyl alcohol, triethyl citrate, triacetin, benzyl acetate, ethyl acetate, propylene glycol (1 ,2-propanediol), 1 ,3-propanediol, dipropylene glycol, glycerol, glycol ethers and mixtures thereof .

The term "biocide" refers to a chemical substance capable of killing living organisms (e.g. microorganisms) or reducing or preventing their growth and/or accumulation. Biocides are commonly used in medicine, agriculture, forestry, and in industry where they prevent the fouling of, for example, water, agricultural products including seed, and oil pipelines. A biocide can be a pesticide, including a fungicide, herbicide, insecticide, algicide, molluscicide, miticide and rodenticide; and/or an antimicrobial such as a germicide, antibiotic, antibacterial, antiviral, antifungal, antiprotozoal and/or antiparasite.

As used herein, a "pest control agent" indicates a substance that serves to repel or attract pests, to decrease, inhibit or promote their growth, development or their activity. Pests refer to any living organism, whether animal, plant or fungus, which is invasive or troublesome to plants or animals, pests include insects notably arthropods, mites, spiders, fungi, weeds, bacteria and other microorganisms.

By "flavor oil", it is meant here a flavoring ingredient or a mixture of flavoring ingredients, solvents or adjuvants of current use for the preparation of a flavoring formulation, i.e. a particular mixture of ingredients which is intended to be added to an edible composition or chewable product to impart, improve or modify its organoleptic properties, in particular its flavor and/or taste. Flavoring ingredients are well known to a person skilled in the art and their nature does not warrant a detailed description here, which in any case would not be exhaustive, the skilled flavorist being able to select them on the basis of his general knowledge and according to the intended use or application and the organoleptic effect it is desired to achieve. Many of these flavoring ingredients are listed in reference texts such as in the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, N.J., USA, or its more recent versions, or in other works of similar nature such as Fenaroli's Handbook of Flavor Ingredients, 1975, CRC Press or Synthetic Food Adjuncts, 1947, by M. B. Jacobs, van Nostrand Co., Inc. Solvents and adjuvants of current use for the preparation of a flavoring formulation are also well known in the art.

In a particular embodiment, the flavor is a mint flavor. In a more particular embodiment, the mint is selected from the group consisting of peppermint and spearmint.

In a further embodiment, the flavor is a cooling agent or mixtures thereof.

In another embodiment, the flavor is a menthol flavor.

Flavors that are derived from or based on fruits where citric acid is the predominant, naturally-occurring acid include but are not limited to, for example, citrus fruits (e.g. lemon, lime), limonene, strawberry, orange, and pineapple. In one embodiment, the flavors food is lemon, lime or orange juice extracted directly from the fruit. Further embodiments of the flavor comprise the juice or liquid extracted from oranges, lemons, grapefruits, key limes, citrons, clementines, mandarins, tangerines, and any other citrus fruit, or variation or hybrid thereof. In a particular embodiment, the flavor comprises a liquid extracted or distilled from oranges, lemons, grapefruits, key limes, citrons, clementines, mandarins, tangerines, any other citrus fruit or variation or hybrid thereof, pomegranates, kiwifruits, watermelons, apples, bananas, blueberries, melons, ginger, bell peppers, cucumbers, passion fruits, mangos, pears, tomatoes, and strawberries.

In a particular embodiment, the flavor comprises a composition that comprises limonene, in a particular embodiment, the composition is a citrus that further comprises limonene.

In another particular embodiment, the flavor comprises a flavor selected from the group comprising strawberry, orange, lime, tropical, berry mix, and pineapple.

The flavoring ingredient may be a taste modifier. A "taste modifier" is understood as an active ingredient that operates on a consumer's taste receptors, or provides a sensory characteristic related to mouthfeel (such as body, roundness, or mouth-coating) to a product being consumed. Non-limiting examples of taste modifiers include active ingredients that enhance, modify or impart saltiness, fattiness, umami, kokumi, heat sensation or cooling sensation, sweetness, acidity, tingling, bitterness or sourness. In a further embodiment, suitable sweetening components may be included in the particles described herein. In a particular embodiment, a sweetening component is selected from the group consisting of sugar (e.g., but not limited to sucrose), a stevia component (such as but not limited to stevioside or rebaudioside A), sodium cyclamate, aspartame, sucralose, sodium saccharine, and Acesulfam K or mixtures thereof.

The flavoring ingredients can be a complex flavor emulating certain organoleptic characteristics, such as sweet and savory tonalities as for example in chicken, beef, pork or shrimp flavor.

The core material may be in the liquid or solid state at temperatures from 20°C to 30°C.

According to an embodiment, the core material is a liquid at temperatures from 20°C to 30°C.

According to another embodiment, the core material is a solid at temperatures from 20°C to 30°C.

The core material may be hydrophobic, meaning it is immiscible with water at temperatures from 20°C to 30°C and is present in the form of a separate, hydrophobic phase.

The core may comprise at least 5 wt.%, more preferably at least 10 wt.%, even more preferably at least 20 wt.%, most preferably at least 30 wt.%, e.g. at least 40 wt.% of chemical compounds possessing a vapor pressure of higher than 0.007 Pa (the vapor pressure being specified for a reference temperature of 25°C).

Preferably, at least 10 wt.% of the core material possess a vapor pressure above 0.1 Pa, more preferably, at least 10 wt.% have a vapor pressure of > 1 Pa at 25°C, and most preferably, at least 10 wt.% have a vapor pressure of > 10 Pa at 25°C.

The given value of 0.007 Pa at 25°C for the vapor pressure is generally regarded as a limiting value identifying compounds with a volatile character. For the purpose of the present invention, the vapor pressures are determined by calculation using the method disclosed in "EPI suite" software; 2000 U.S. Environmental Protection Agency.

Preferably, the core of the coacervate core-shell microcapsule comprises the flavor ingredient. In other words, the flavor ingredient is encapsulated in the core of the coacervate core-shell microcapsule.

The core of the coacervate core-shell microcapsule may comprise a fat matrix, preferably wherein the fat matrix comprises food grade oils.

According to an embodiment, the core comprises fat and/or wax.

The fat matrix may comprise (i) a hydrogenated oil or (ii) a hydrogenated fat or (iii) cocoa butter or (iv) a mixture of i-iii.

Preferably, hydrogenated oils include hydrogenated palm oil, hydrogenated soybean oil and hydrogenated cottonseed oil. Preferably, hydrogenated fat includes cocoa fat.

More preferably, the fat matrix comprises a mixture of a fat and a hydrogenated oil. Even more preferably, the fat matrix comprises a mixture of hydrogenated palm oil with coco fat and/or cocoa butter.

According to a particular embodiment, the shell of the microcapsules further comprises an additional polymeric material, wherein said polymeric material is preferably chosen in the group consisting of polyurea, polyurethane, polyamide, polyester, polyacrylate, polysiloxane, polycarbonate, polysulfonamide, polymers of urea and formaldehyde, melamine and formaldehyde, melamine and urea, or melamine and glyoxal and mixtures thereof.

According to a particular embodiment, the shell of the microcapsules comprises polyurea.

According to a particular embodiment, the shell of the microcapsules is free from additional polymeric material.

According to an embodiment, the shell is a composite shell made of a coacervate material and a polymeric material.

According to a particular embodiment, the additional polymeric material forms an inner layer.

According to an embodiment, the microcapsule shell comprises an inner layer made of a polymeric material and an outer coacervate layer comprising the moringa oleifera extract.

According to the invention, the shell is cross-linked.

The shell of the microcapsule may be cross-linked using different type of cross-linking agents. Typically, a cross-linking agent may be used to harden the microcapsule shell.

The cross-linking agents may include formaldehyde, genipin, tannins (such as polyphenols), acetaldehyde, glutaraldehyde, glyoxal, chrome alum or transglutaminase.

Typically, the cross-linker is used in an amount comprised between 0.001 and 5%, preferably between 0.005 and 2% based on the total weight of the emulsion and/or suspension (slurry).

According to an embodiment, the cross-linking agent is glutaraldehyde and is typically used in an amount comprised between 0.005 and 5% by weight based on the total weight of the emulsion and/or suspension (slurry).

Glutaraldehyde is well described in the public domain and commercially available.

According to another embodiment, the cross-linking agent is an enzyme, typically, transglutaminase.

In some commercial products, the enzyme is dispersed in a carrier. One may cite for example Activa® Tl (Origin: Ajinomoto). In other words, the commercial product is added in the process so as to have the enzyme actives in an amount preferably between 0.001 to 5%, preferably from 0.001 to 1 %, even more preferably 0.001 and 0.1%, and even more preferably between 0.005 and 0.02% based on the protein content and total weight of the of the emulsion and/or suspension (slurry).

Action required to induce the cross-linking of the moringa oleifera extract by the crosslinker is well known by the skilled person in the art.

Preferably, the cross-linking is conducted at a temperature within the range of 5 to 60°C, preferably 15 to 50°C, more preferably 20 to 45°C.

Preferably, the pH during the cross-linking is adjusted to a level at which cross-linking can be conducted effectively. Preferably, if cross-linking is performed enzymatically using transglutaminase, the pH may be adjusted to 43 to 8, more preferably 4 to 7.

Preferably, the cross-linking is carried out for a time period of from 1 to 20 h, preferably from 2 h to 12 h, more preferably from 7 h to 10 h,

Alternatively, the cross-linking is carried out for a time period of from 1 to 15 h, preferably from 1 to 4 h.

When the cross-linker is an enzyme, a heating treatment can be performed on the slurry to deactivate the enzyme. Typically, the heating treatment is performed at a temperature comprised between 70 °C and 90 °C.

Alternatively, the shell may also be hardened by other methods different from crosslinking using the aforementioned cross-linking agents. Such methods comprise (i) hardening of the shell by thermal annealing, which is achieved by heating the capsules; preferably, the heating is performed at a temperature close to the denaturation temperature of the protein, and most preferably at the or above the denaturation temperature of the protein; (ii) hardening the shell by a change in pH (which may be referred to as a ‘pH quench’) to range wherein the shell's density is increased; (iii) hardening the shell by a change in ionic strength to range wherein the protein’s wherein the shell's density is increased, which may be achieved by addition of solutes, preferably by addition of salt; (iv) hardening the shell by modifying continuous water phase by addition of water-miscible additives such that the wherein the shell's density is increased, preferably by addition of glycerol, propylene glycol, ethanol or isopropanol; (v) hardening the shell by any combination of methods i-iv, either in sequence, simultaneously, or by combining any of methods i-iv both in sequence and simultaneously.

According to a particular embodiment, the shell is cross-linked only by a thermal treatment.

When the shell comprises an additional polymeric material, said polymeric material can act as a cross-linking agent.

In a particular embodiment, the shell material is a biodegradable material. In a particular embodiment, the shell has a biodegradability of at least 40%, preferably at least 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98%, within 60 days according to OECD301 F.

In a particular embodiment, the core-shell microcapsule has a biodegradability of at least 40 %, preferably at least 60 %, preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% within 60 days according to OECD301 F.

Thereby it is understood that the core-shell microcapsule including all components, such as the core, shell and optionally coating may have a biodegradability of at least 40 %, preferably at least 60 %, preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% within 60 days according to OECD301 F.

In a particular embodiment, the oil-based core, preferably perfume oil has a biodegradability of at least 40 %, preferably at least 60 %, preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% within 60 days according to OECD301 F.

OECD301 F is a standard test method on the biodegradability from the Organization of Economic Co-operation and Development.

A typical method for extracting the shell for measuring the biodegradability is disclosed in Gaspari ni and all in Molecules 2020, 25, 718.

Outer coating

According to a particular embodiment of the invention, microcapsules according to the invention comprise an outer coating material selected from the group consisting of a polysaccharide, a cationic polymer, a polysuccinimide derivative (as described for instance in WO2021185724), a moringa extract and mixtures thereof to form an outer coating to the microcapsule.

Polysaccharide polymers are well known to a person skilled in the art. Preferred polysaccharides are selected from the group consisting of locust bean gum, xyloglucan, guar gum, hydroxypropyl guar, hydroxypropyl cellulose and hydroxypropyl methyl cellulose, pectin and mixtures thereof.

According to a particular embodiment, the coating consists of a cationic coating.

Cationic polymers are also well known to a person skilled in the art. Preferred cationic polymers have cationic charge densities of at least 0.5 meq/g, more preferably at least about 1.5 meq/g, but also preferably less than about 7 meq/g, more preferably less than about 6.2 meq/g. The cationic charge density of the cationic polymers may be determined by the Kjeldahl method as described in the US Pharmacopoeia under chemical tests for Nitrogen determination. The preferred cationic polymers are chosen from those that contain units comprising primary, secondary, tertiary and/or quaternary amine groups that can either form part of the main polymer chain or can be borne by a side substituent directly connected thereto. The weight average (Mw) molecular weight of the cationic polymer is preferably between 10,000 and 3.5M Dalton, more preferably between 50,000 and 2M Dalton.

According to a particular embodiment, one will use cationic polymers based on acrylamide, methacrylamide, N-vinylpyrrolidone, quaternized N,N- dimethylaminomethacrylate, diallyldimethylammonium chloride, quaternized vinylimidazole (3-methyl-1-vinyl-1 H-imidazol-3-ium chloride), vinylpyrrolidone, acrylamidopropyltrimonium chloride, cassia hydroxypropyltrimonium chloride, guar hydroxypropyltrimonium chloride or polygalactomannan 2-hydroxypropyltrimethylammonium chloride ether, starch hydroxypropyltrimonium chloride and cellulose hydroxypropyltrimonium chloride. Preferably copolymers shall be selected from the group consisting of polyquaternium-5, polyquaternium- 6, polyquaternium-7, polyquaterniumIO, polyquaternium-11 , polyquaternium-16, polyquaternium-22, polyquaternium-28, polyquaternium-43, polyquaternium-44, polyquaternium-46, cassia hydroxypropyltrimonium chloride, guar hydroxypropyltrimonium chloride or polygalactomannan 2-hydroxypropyltrimethylammonium chloride ether, starch hydroxypropyltrimonium chloride and cellulose hydroxypropyltrimonium chloride.

As specific examples of commercially available products, one may cite Salcare®SC60 (cationic copolymer of acrylamidopropyltrimonium chloride and acrylamide, origin: BASF) or Luviquat®, such as the PQ 11 N, FC 550 or Style (polyquaternium-11 to 68 or quaternized copolymers of vinylpyrrolidone origin: BASF), or also the Jaguar® (C13S or C17, origin Rhodia).

According to any one of the above embodiments of the invention, there is added an amount of polymer described above comprised between about 0% and 5% w/w, or even between about 0.1% and 2% w/w, percentage being expressed on a w/w basis relative to the total weight of the slurry. It is clearly understood by a person skilled in the art that only part of said added polymers will be incorporated into/deposited on the microcapsule shell.

Another object of the invention is a process for preparing the coacervate core-shell microcapsules as defined above, wherein the process comprises the steps of: a) preparing a solution by dissolving at least one Moringa oleifera extract in aqueous solution, preferably water; b) optionally, preparing a solution by dissolving at least one non-protein polymer and/or at least one protein polymer in aqueous solution, preferably water; c) optionally, mixing the prepared solutions comprising at least one plant protein extract and at least one non-protein polymer and/or at least one protein polymer; d) preparing, an emulsion and/or suspension by emulsifying and/or suspending a hydrophobic material and optionally a polyfunctional monomer in the solution; e) forming a coacervate shell comprising the Moringa oleifera extract and optionally the non-protein polymer and/or the protein polymer around droplets and/or particles of the hydrophobic material present in an emulsion and/or suspension; and f) cross-linking the shell.

According to an embodiment, the aqueous phase also comprises an alcohol such as such as glycerol, 1 ,4-butanediol, ethylene glycol, propylene glycol and mixtures thereof.

According to an embodiment, the aqueous phase consists of water.

It is understood that any of the steps c-e may be performed sequentially or simultaneously.

In another embodiment, any one or several of the process steps a) to e) described hereabove may additionally contain a dilution step in which additional solvent, preferably water, is added to any of the solutions or their mixtures.

In a particular alternative embodiment, process step e) as described hereabove additionally comprises modifying the pH value of the mixture.

While it is understood that the above order of process steps is the preferred order, it may be possible to change the order of some of the steps. In a particular alternative embodiment, step c ) may be performed after step d), meaning the hydrophobic material is first emulsified in the solution prepared in step a), and the solution prepared in step b) is only added after emulsification.

In another particular alternative embodiment, step e) is performed before step d), meaning that the coacervates are first formed followed by the addition of a hydrophobic material and optionally a polyfunctional monomer.

According to a particular embodiment, the Moringa oleifera seed extract is obtained by an extraction of a Moringa oleifera seed flour, carried out typically at a pH between 3 and 10, preferably between 4 and 7.

Typically, the extraction is carried out by dispersing Moringa oleifera seed flour in water, adjusting the pH value to a range of 3 to 10, heat the solution at a temperature comprised between 40 and 70 centrifuging said dispersion and collecting the extract which is present as the protein-rich supernatant. The collected supernatant is then freeze dried or spray dried to obtain a soluble moringa protein powder. In the process of the present invention, the first solution may comprise dissolving at least one Moringa oleifera extract, in aqueous solution, preferably water,

In the first solution, the protein Moringa extract may be present in the aqueous solution in an amount of from 0.5 to 30 wt%, more preferably from 1 to 15 wt%, even more preferably from 5 to 15 wt%.

The second solution may comprise dissolving at least one non-protein polymer or polyelectrolyte, preferably gum arabic, in aqueous solution, preferably water,

Optionally, in the second solution, the non-protein polymer or polyelectrolyte may be present in the aqueous solution in an amount from 0.5 to 20 wt%, more preferably from 1 to 15 wt%, even more preferably from 5 to 15 wt%.

The first solution is then diluted, preferably lower than 90% initial concentration, to form the coacervates. Indeed, it has been found that the dilution of the solution can induce the coacervates formation. Typically, after the dilution step, the concentration of the Moringa extract in the aqueous phase is comprised between 0.5 and 15%, preferably between 1 and 10%.

Optionally, the first and second solution may be mixed under agitation to form the third solution.

Optionally, the pH of the third aqueous solution may be adjusted to a pH value below 4.7, preferably below 4.3 and most preferably below 3.5.

The pH of the third aqueous solution may be adjusted by the addition of a food grade acid solution, preferably by addition of an aqueous lactic acid solution.

The hydrophobic material may be introduced into the first or the third solution under shear to form an emulsion or suspension.

The emulsion or suspension may be prepared in a conventional manner.

The emulsion or suspension may be prepared by adding the hydrophobic material to the third solution over a period of about 3 to 10 minutes, preferably 4 to 6 minutes.

The emulsion or suspension may be prepared with an impeller stirrer being adjusted to a speed of 300 to 400 rpm. The stirrer speed may be adjusted as desired.

In this step, also known as the "coacervation" step, two separate phases may be created, namely, the coacervate phase (enriched in polymer) and the coexisting solvent (depleted of polymer). The coacervate phase may be generally composed of the Moringa oleifera extract and, optionally, the non-protein polymer.

The coacervation may be facilitated by modifying the pH

The pH is adjusted by the addition of a food grade acid or base solution, preferably by addition of an aqueous lactic acid solution, and sodium hydroxide solution. Phase separation may be also induced by various other ways by changing the physicochemical environment of the solution, e.g. salting out or addition of a second high- molecular weight component so as to induce phase separation,

According to a particular embodiment, when the core-shell microcapsule comprises an additional polymeric material, a polyfunctional monomer is added in the oil phase (in addition to the hydrophobic material) and/or in the water phase.

According to a particular embodiment, a reactant is added during the process, preferably in the water phase. Examples of suitable reactant include alcohols, amines, phenols, thiols.

By “polyfunctional monomer”, it is meant a molecule that, as unit, reacts or binds chemically to form a polymer or supramolecular polymer. The polyfunctional polymer of the invention has at least two functions capable of forming a microcapsule shell.

The polyfunctional monomer can be chosen in the group consisting of at least one polyisocyanate, poly maleic anhydride, poly acid chloride, polyepoxide, acrylate monomers, polyalkoxysilane , melamine-based resin and mixtures thereof.

According to a particular embodiment, the polyfunctional monomer used in the process according to the invention is present in amounts representing from 0.1 to 15%, preferably from 0.5 to 10% and more preferably from 0.8 to 6%, and even more preferably between 1 and 3% by weight of the oil phase or of the water phase.

According to a particular embodiment, the monomer added in step a) is at least one polyisocyanate having at least two isocyanate functional groups.

Suitable polyisocyanates used according to the invention include aromatic polyisocyanate, aliphatic polyisocyanate and mixtures thereof. Said polyisocyanate comprises at least 2, preferably at least 3 but may comprise up to 6, or even only 4, isocyanate functional groups. According to a particular embodiment, a triisocyanate (3 isocyanate functional group) is used.

According to one embodiment, said polyisocyanate is an aromatic polyisocyanate.

The term “aromatic polyisocyanate” is meant here as encompassing any polyisocyanate comprising an aromatic moiety. Preferably, it comprises a phenyl, a toluyl, a xylyl, a naphthyl or a diphenyl moiety, more preferably a toluyl or a xylyl moiety. Preferred aromatic polyisocyanates are biurets, polyisocyanurates and trimethylol propane adducts of diisocyanates, more preferably comprising one of the above-cited specific aromatic moieties. More preferably, the aromatic polyisocyanate is a polyisocyanurate of toluene diisocyanate (commercially available from Bayer under the tradename Desmodur® RC), a trimethylol propane-adduct of toluene diisocyanate (commercially available from Bayer under the tradename Desmodur® L75), a trimethylol propane-adduct of xylylene diisocyanate (commercially available from Mitsui Chemicals under the tradename Takenate® D-110N). In a most preferred embodiment, the aromatic polyisocyanate is a trimethylol propane-adduct of xylylene diisocyanate.

According to another embodiment, said polyisocyanate is an aliphatic polyisocyanate. The term “aliphatic polyisocyanate” is defined as a polyisocyanate which does not comprise any aromatic moiety. Preferred aliphatic polyisocyanates are a trimer of hexamethylene diisocyanate, a trimer of isophorone diisocyanate, a trimethylol propane-adduct of hexamethylene diisocyanate (available from Mitsui Chemicals) or a biuret of hexamethylene diisocyanate (commercially available from Bayer under the tradename Desmodur® N 100), among which a biuret of hexamethylene diisocyanate is even more preferred.

According to another embodiment, the at least one polyisocyanate is in the form of a mixture of at least one aliphatic polyisocyanate and of at least one aromatic polyisocyanate, both comprising at least two or three isocyanate functional groups, such as a mixture of a biuret of hexamethylene diisocyanate with a trimethylol propane-adduct of xylylene diisocyanate, a mixture of a biuret of hexamethylene diisocyanate with a polyisocyanurate of toluene diisocyanate and a mixture of a biuret of hexamethylene diisocyanate with a trimethylol propane-adduct of toluene diisocyanate. Most preferably, it is a mixture of a biuret of hexamethylene diisocyanate with a trimethylol propane-adduct of xylylene diisocyanate. Preferably, when used as a mixture the molar ratio between the aliphatic polyisocyanate and the aromatic polyisocyanate is ranging from 80:20 to 10:90.

According to an embodiment, the polyfunctional monomer is an acyl chloride.

According to a particular embodiment, the acyl chloride has the following formula (I) ©

wherein n is an integer varying between 1 and 8, preferably between 1 and 6, more preferably between 1 and 4, and wherein X is an (n+1)-valent C2 to C45 hydrocarbon group optionally comprising at least one group selected from (i) to (xi), particularly from (i) to (vi)

wherein R is a hydrogen atom or an alkyl group such as a methyl or an ethyl group, preferably a hydrogen atom.

It is understood that by hydrocarbon group ...” it is meant that said group consists of hydrogen and carbon atoms and can be in the form of an aliphatic hydrocarbon, i.e. linear or branched saturated hydrocarbon (e.g. alkyl group), a linear or branched unsaturated hydrocarbon (e.g. alkenyl or alkynil group), a saturated cyclic hydrocarbon (e.g. cycloalkyl) or an unsaturated cyclic hydrocarbon (e.g. cycloalkenyl or cycloalkynyl), or can be in the form of an aromatic hydrocarbon, i.e. aryl group, or can also be in the form of a mixture of said type of groups, e.g. a specific group may comprise a linear alkyl, a branched alkenyl (e.g. having one or more carbon-carbon double bonds), a (poly)cycloalkyl and an aryl moiety, unless a specific limitation to only one type is mentioned. Similarly, in all the embodiments of the invention, when a group is mentioned as being in the form of more than one type of topology (e.g. linear, cyclic or branched) and/or being saturated or unsaturated (e.g. alkyl, aromatic or alkenyl), it is also meant a group which may comprise moieties having any one of said topologies or being saturated or unsaturated, as explained above. Similarly, in all the embodiments of the invention, when a group is mentioned as being in the form of one type of saturation or unsaturation, (e.g. alkyl), it is meant that said group can be in any type of topology (e.g. linear, cyclic or branched) or having several moieties with various topologies.

It is understood that with the term a hydrocarbon group, optionally comprising ...” it is meant that said hydrocarbon group optionally comprises heteroatoms to form ether, thioether, amine, nitrile or carboxylic acid groups and derivatives (including for example esters, acids, amide). These groups can either substitute a hydrogen atom of the hydrocarbon group and thus be laterally attached to said hydrocarbon, or substitute a carbon atom (if chemically possible) of the hydrocarbon group and thus be inserted into the hydrocarbon chain or ring. According to a particular embodiment, the acyl chloride is chosen from the group consisting of benzene- 1 , 3, 5-tricarbonyl trichloride (trimesoyl trichloride), benzene-1 ,2,4- tricarbonyl trichloride, benzene-1 ,2,4,5-tetracarbonyl tetrachloride, cyclohexane- 1 ,3,5- tricarbonyl trichloride, isophthalyol dichloride, diglycolyl dichloride, phthaloyl chloride, isophthaloyl chloride, terephthaloyl chloride, fumaryl dichloride, adipoyl chloride, succinic dichloride, propane-1 , 2, 3-tricarbonyl trichloride, cyclohexane-1 ,2,4,5-tetracarbonyl tetrachloride, 2,2'-disulfanediyldisuccinyl dichloride, 2-(2-chloro-2-oxo- ethyl)sulfanylbutanedioyl dichloride, (4-chloro-4-oxobutanoyl)-L-glutamoyl dichloride, (S)-4- ((1 ,5-dichloro-1 ,5-dioxopentan-2-yl)amino)-4-oxobutanoic acid, 2,2-bis[(4-chloro-4-oxo- butanoyl)oxymethyl]butyl 4-chloro-4-oxo-butanoate, [2-[2,2-bis[(4-chloro-4-oxo- butanoyl)oxymethyl]butoxymethyl]-2-[(4-chloro-4-oxo-butanoyl)oxymethyl]butyl] 4-chloro-4- oxo-butanoate, 2,2-bis[(2-chlorocarbonylbenzoyl)oxymethyl]butyl 2-chlorocarbonyl-benzoate, [2-[2,2-bis[(2-chlorocarbonylbenzoyl)oxymethyl]butoxymethyl]-2-[(2- chlorocarbonylbenzoyl)oxymethyl]butyl] 2-chlorocarbonylbenzoate, 4-(2,4,5- trichlorocarbonylbenzoyl)oxybutyl 2,4,5-trichlorocarbonyl-benzoate, propane-1 ,2, 3-triyl tris(4- chloro-4-oxobutanoate), propane- 1 ,2-diyl bis(4-chloro-4-oxobutanoate) and mixtures thereof.

Another object of the present invention is a coacervate core-shell microcapsules obtainable by the process as defined above.

Another object of the invention is a process for preparing a microcapsule powder comprising the steps as defined above and an additional step consisting of submitting the slurry obtained in step e) or f) to a drying, like spray-drying, to provide the microcapsules as such, i.e. in a powdery form. It is understood that any standard method known by a person skilled in the art to perform such drying is also applicable. In particular the slurry may be spray- dried preferably in the presence of a polymeric carrier material such as polyvinyl acetate, polyvinyl alcohol, dextrins, natural or modified starch, vegetable gums, pectins, xanthans, alginates, carragenans or cellulose derivatives to provide microcapsules in a powder form.

However, one may cite also other drying method such as the extrusion, plating, spray granulation, the fluidized bed, or even a drying at room temperature using materials (carrier, desiccant) that meet specific criteria as disclosed in WO2017/134179.

According to a particular embodiment, the carrier material contains free hydrophobic material which can be same or different from the hydrophobic material from the core of the microcapsules.

Optional components When microcapsules are in the form of a slurry, the microcapsule slurry can comprise auxiliary ingredients selected from the group of thickening agents/rheology modifiers, antimicrobial agents, opacity-building agents, mica particles, salt, pH stabilizers/buffering ingredients, preferably in an amount comprised between 0 and 15% by weight based on the total weight of the slurry.

According to another embodiment, the microcapsule slurry of the invention comprises additional free (i.e non-encapsulated) perfume, preferably in an amount comprised between 5 and 50% by weight based on the total weight of the slurry.

Multiple microcapsule system

According to an embodiment, the microcapsules of the invention (first type of microcapsule) can be used in combination with a second type of microcapsules.

Another object of the invention is a microcapsule delivery system comprising: the microcapsules of the present invention as a first type of microcapsule, and a second type of microcapsules, wherein the first type of microcapsule and the second type of microcapsules differ in their hydrophobic material and/or their wall material and/or their coacervate particles and/or in their coating material.

According to a particular embodiment, the microcapsule delivery system is in the form of a slurry.

Consumer products

By “consumer product” or “end-product” it is meant a manufactured product ready to be distributed, sold and used by a consumer.

The microcapsules of the invention can be used for the preparation of perfuming or flavouring compositions which are also an object of the invention.

Flavored consumer products

The microcapsules of the invention can be used in a great variety of edible end products.

End products are more particularly a food, pet-food or feed products. As the microcapsules of the invention are plant based microcapsules, they are particularly advantageous for vegetarian meat analogues or meat replacers, vegetarian burger, sausages, patties, chicken-imitate nuggets... , meat products (e.g. processed meat, poultry, beef, pork, ham, fresh sausage or raw meat preparations, spiced or marinated fresh meat or cured meat products, reformed meat) or extended meat products making use of a combination of animal and vegetable protein in varying ratios, often being coextruded or a mix between textured vegetable protein and animal protein.

Meat, for the purpose of the present invention, encompasses red meat, such as beef, pork, sheep, lamb, game and poultry, such as chicken, turkey, goose and duck. Preferably, the food of the present invention is meat selected from beef, poultry and pork.

In one aspect, the flavored consumer product is selected from the group consisting of: protein powders, protein drinks, protein bars, meat analogues, seefood analogues and savory goods.

Meat analogues can include pork analogues, venison analogues, beef analogues, veal analogues, rabbit analogues, sausage analogues, deli meat analogues, ham analogues, salami analogues, pepperoni analogues, chicken analogues, turkey analogues, goose analogues, pheasant analogues, pigeon analogues, whale analogues, lamb analogues, goat analogues, donkey analogues, and squirrel analogues.

Seafood analogues can include fish analogues, scallop analogues, shrimp analogues, crabmeat analogues, shellfish analogues, clam analogues, squid analogues, conch analogues, and sea pineapple analogues.

When the flavored consumer product is a particulate or powdery food, the dry particles may easily be added thereto by dry-mixing. Typical flavored articles are selected from the group consisting of an instant soup or sauce, a breakfast cereal, a powdered milk, a baby food, a powdered drink, a powdered chocolate drink, a spread, a powdered cereal drink, a chewing gum, an effervescent tablet, a cereal bar, and a chocolate bar. The powdered foods or drinks may be intended to be consumed after reconstitution of the product with water, milk and/or a juice, or another aqueous liquid.

The dry particles provided herein may be suitable for conveying flavors to beverages, fluid dairy products, condiments, baked goods, frostings, bakery fillings, candy, chewing gum and other food products.

Beverages include, without limitation, carbonated soft drinks, including cola, lemonlime, root beer, heavy citrus (“dew type”), fruit flavored and cream sodas; powdered soft drinks, as well as liquid concentrates such as fountain syrups and cordials; coffee and coffee-based drinks, coffee substitutes and cereal-based beverages; teas, including dry mix products as well as ready-to-drink teas (herbal and tealeaf based); fruit and vegetable juices and juice flavored beverages as well as juice drinks, nectars, concentrates, punches and “ades”; sweetened and flavored waters, both carbonated and still; sport/energy/health drinks; alcoholic beverages plus alcohol-free and other low-alcohol products including beer and malt beverages, cider, and wines (still, sparkling, fortified wines and wine coolers); other beverages processed with heating (infusions, pasteurization, ultra-high temperature, ohmic heating or commercial aseptic sterilization) and hot-filled packaging; and cold-filled products made through filtration or other preservation techniques.

Fluid dairy products include, without limitation, non-frozen, partially frozen and frozen fluid dairy products such as, for example, milks, ice creams, sorbets and yogurts.

Condiments include, without limitation, ketchup, mayonnaise, salad dressing, Worcestershire sauce, fruit-flavored sauce, chocolate sauce, tomato sauce, chili sauce, and mustard.

Baked goods include, without limitation, cakes, cookies, pastries, breads, donuts and the like. Bakery fillings include, without limitation, low or neutral pH fillings, high, medium or low solids fillings, fruit or milk based (pudding type or mousse type) fillings, hot or cold make-up fillings and nonfat to full-fat fillings.

Nevertheless, the microcapsules of the invention can also be of particular interest in the following examples of products:

• Baked goods (e.g. bread, dry biscuits, cakes, other baked goods),

• Non-alcoholic beverages (e.g. carbonated soft drinks, bottled waters , sports/energy drinks , juice drinks, vegetable juices, vegetable juice preparations),

• Alcoholic beverages (e.g. beer and malt beverages, spirituous beverages),

• Instant beverages (e.g. instant vegetable drinks, powdered soft drinks, instant coffee and tea),

• Cereal products (e.g. breakfast cereals, pre-cooked ready-made rice products, rice flour products, millet and sorghum products, raw or pre-cooked noodles and pasta products),

• Milk products (e.g. fresh cheese, soft cheese, hard cheese, milk drinks, whey, butter, partially or wholly hydrolysed milk protein-containing products, fermented milk products, condensed milk and analogues),

• Dairy based products (e.g. fruit or flavored yoghurt, ice cream, fruit ices)

• Confectionary products (e.g. chewing gum, hard and soft candy)

• Chocolate and compound coatings

• Products based on fat and oil or emulsions thereof (e.g. mayonnaise, spreads, margarines, shortenings, remoulade, dressings, spice preparations),

• Spiced, marinated or processed fish products (e.g. fish sausage, surimi),

• Eggs or egg products (dried egg, egg white, egg yolk, custard),

• Desserts (e.g. gelatins and puddings)

• Products made of soya protein or other soya bean fractions (e.g. soya milk and products made therefrom, soya lecithin-containing preparations, fermented products such as tofu or tempeh or products manufactured therefrom, soya sauces), • Vegetable preparations (e.g. ketchup, sauces, processed and reconstituted vegetables, dried vegetables, deep frozen vegetables, pre-cooked vegetables, vegetables pickled in vinegar, vegetable concentrates or pastes, cooked vegetables, potato preparations),

• Vegetarian meat replacer, vegetarian burger

• Spices or spice preparations (e.g. mustard preparations, horseradish preparations), spice mixtures and, in particular seasonings which are used, for example, in the field of snacks.

• Snack articles (e.g. baked or fried potato crisps or potato dough products, bread dough products, extrudates based on maize, rice or ground nuts),

• Meat products (e.g. processed meat, poultry, beef, pork, ham, fresh sausage or raw meat preparations, spiced or marinated fresh meat or cured meat products, reformed meat),

• Ready dishes (e.g. instant noodles, rice, pasta, pizza, tortillas, wraps) and soups and broths (e.g. stock, savory cube, dried soups, instant soups, pre-cooked soups, retorted soups), sauces (instant sauces, dried sauces, ready-made sauces, gravies, sweet sauces).

Preferably, the microcapsules according to the invention shall be used in products selected from the group consisting of baked goods, instant beverages, cereal products, milk products, dairy-based products, products based on fat and oil or emulsions thereof, desserts, vegetable preparations, vegetarian meat replacer, spices and seasonings, snacks, meat products, ready dishes, soups and broths and sauces.

According to a particular embodiment, the flavored product is chosen group consisting of a meat- and/or fish-based food or analogue, a stock, a savory cube, a powder mix, a beef or pork based product, a seafood, surimi, instant noodles, rice, soups, sauces, ready-made meal, frozen or chilled pizza, pasta, potato flakes or fried, noodles, a potato/tortilla chip, a microwave popcorn, nuts , a bretzel, a rice cake, a rice cracker, fermented dairy analogue beverage, acidified dairy analogue beverage, non-fermented dairy analogue beverage, cheese or cheese analogue, yoghurt or yoghurt analogue, nutritional supplement, nutritional bar, cereal, ice cream, dairy-free ice cream, confectionary product, chewing gum, hard-boiled candy and powdered drinks.

According to one embodiment, the food, pet-food or feed product comprises between 0.01 and 10% by weight, preferably between 0.1 and 5% by weight of the microcapsules of the invention.

Typically the food, pet-food or feed product further comprises proteins notably vegetable proteins or animal proteins, and mixtures thereof. Advantageously the vegetable proteins are preferably selected among soy protein, corn, peas, canola, sunflowers, sorghum, rice, amaranth, potato, tapioca, arrowroot, chickpeas, lupins, canola, wheat, oats, rye, barley, and mixtures thereof.

The microcapsules of the invention are particularly suitable for extruded and/or baked food, pet-food or feed products more particularly comprising animal and/or vegetable proteins. Typically, said extruded and/or baked food, pet-food or feed products may be selected among meat- and/or fish-based food or analogue and mixtures thereof (in other words, meat-based food and/or fish-based food or meat analogue or fish analogue and mixtures thereof); extruded and/or baked meat analogue or extruded and/or baked fish analogue are preferred. Nonlimiting examples of extruded and/or baked food, pet-food or feed products are snack products or extruded vegetable proteins with the aim to texture the protein from which meat analogous (e.g. burgers) are prepared from. The powder composition can be added pre-extrusion or after extrusion to either, the non-extruded vegetable protein isolate/concentrate or to the textured vegetable protein from which a burger or nugget (etc.) is formed.

PERFUMING COMPOSITION AND CONSUMER PRODUCTS

The microcapsules of the invention can be used in combination with active ingredients. An object of the invention is therefore a composition comprising:

(i) microcapsules or a microcapsule slurry as defined above;

(ii) an active ingredient, preferably chosen in the group consisting of a cosmetic ingredient, skin caring ingredient, perfume ingredient, flavor ingredient, malodour counteracting ingredient, bactericide ingredient, fungicide ingredient, pharmaceutical or agrochemical ingredient, a sanitizing ingredient, an insect repellent or attractant, and mixtures thereof.

The microcapsules of the invention show a good performance in terms of stability in challenging medium.

Another object of the present invention is a perfuming composition comprising:

(i) microcapsules or a microcapsule slurry as defined above, wherein the oil comprises a perfume;

(ii) at least one ingredient selected from the group consisting of a perfumery carrier, a perfumery co-ingredient and mixtures thereof;

(iii) optionally at least one perfumery adjuvant.

As liquid perfumery carriers one may cite, as non-limiting examples, an emulsifying system, i.e. a solvent and a surfactant system, or a solvent commonly used in perfumery. A detailed description of the nature and type of solvents commonly used in perfumery cannot be exhaustive. However, one can cite as non-limiting examples solvents such as dipropyleneglycol, diethyl phthalate, isopropyl myristate, benzyl benzoate, 2-(2- ethoxyethoxy)-1 -ethanol or ethyl citrate, which are the most commonly used. For the compositions which comprise both a perfumery carrier and a perfumery co-ingredient, other suitable perfumery carriers than those previously specified, can be also ethanol, water/ethanol mixtures, limonene or other terpenes, isoparaffins such as those known under the trademark Isopar™ (origin: Exxon Chemical) or glycol ethers and glycol ether esters such as those known under the trademark Dowanol™ (origin: Dow Chemical Company). By “perfumery coingredient” it is meant here a compound, which is used in a perfuming preparation or a composition to impart a hedonic effect and which is not a microcapsule as defined above. In other words such a co-ingredient, to be considered as being a perfuming one, must be recognized by a person skilled in the art as being able to at least impart or modify in a positive or pleasant way the odor of a composition, and not just as having an odor.

The nature and type of the perfuming co-ingredients present in the perfuming composition do not warrant a more detailed description here, which in any case would not be exhaustive, the skilled person being able to select them on the basis of his general knowledge and according to the intended use or application and the desired organoleptic effect. In general terms, these perfuming co-ingredients belong to chemical classes as varied as alcohols, lactones, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogenous or sulfurous heterocyclic compounds and essential oils, and said perfuming co-ingredients can be of natural or synthetic origin. Many of these co-ingredients are in any case listed in reference texts such as the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its more recent versions, or in other works of a similar nature, as well as in the abundant patent literature in the field of perfumery. It is also understood that said co-ingredients may also be compounds known to release in a controlled manner various types of perfuming compounds. Co-ingredients may be chosen in the group consisting of 4- (dodecylthio)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-butanone, 4-(dodecylthio)-4-(2,6,6- trimethyl-1-cyclohexen-1-yl)-2-butanone, trans-3-(dodecylthio)-1-(2,6,6-trimethyl-3- cyclohexen-1-yl)-1-butanone, 2-(dodecylthio)octan-4-one, 2-phenylethyl oxo(phenyl)acetate, 3,7-dimethylocta-2,6-dien-1-yl oxo(phenyl)acetate, (Z)-hex-3-en-1-yl oxo(phenyl)acetate, 3,7- dimethyl-2,6-octadien-1-yl hexadecanoate, bis(3,7-dimethylocta-2,6-dien-1-yl) succinate, (2- ((2-methylundec-1-en-1-yl)oxy)ethyl)benzene, 1-methoxy-4-(3-methyl-4-phenethoxybut-3-en- 1-yl)benzene, (3-methyl-4-phenethoxybut-3-en-1-yl)benzene, 1-(((Z)-hex-3-en-1-yl)oxy)-2- methylundec-1-ene, (2-((2-methylundec-1-en-1-yl)oxy)ethoxy)benzene, 2-methyl-1-(octan-3- yloxy)undec-1 -ene, 1 -methoxy-4-(1 -phenethoxyprop-1 -en-2-yl)benzene, 1 -methyl-4-(1 - phenethoxyprop- 1-en-2-yl)benzene, 2-(1 -phenethoxyprop- 1-en-2-yl)naphthalene, (2- phenethoxyvinyl)benzene, 2-(1-((3,7-dimethyloct-6-en-1-yl)oxy)prop-1-en-2-yl)naphthalene, (2-((2-pentylcyclopentylidene)methoxy)ethyl)benzene, 4-allyl-2-methoxy-1-((2-methoxy-2- phenylvinyl)oxy)benzene, (2-((2-heptylcyclopentylidene)methoxy)ethyl)benzene, 1-isopropyl- 4-methyl-2-((2-pentylcyclopentylidene)methoxy)benzene, 2-methoxy-1-((2- pentylcyclopentylidene)methoxy)-4-propylbenzene, 3-methoxy-4-((2-methoxy-2- phenylvinyl)oxy)benzaldehyde, 4-((2-(hexyloxy)-2-phenylvinyl)oxy)-3-methoxybenzaldehyde or a mixture thereof or a mixture thereof.

By “perfumery adjuvant” we mean here an ingredient capable of imparting additional added benefit such as a color, a particular light resistance, chemical stability, etc. A detailed description of the nature and type of adjuvant commonly used in perfuming bases cannot be exhaustive, but it has to be mentioned that said ingredients are well known to a person skilled in the art.

Preferably, the perfuming composition according to the invention comprises between 0.01 and 30 % by weight of microcapsules as defined above.

The invention’s microcapsules can advantageously be used in many application fields and used in consumer products. Microcapsules can be used in liquid form applicable to liquid consumer products as well as in powder form, applicable to powder consumer products.

According to a particular embodiment, the consumer product as defined above is liquid and comprises: a) from 2 to 65% by weight, relative to the total weight of the consumer product, of at least one surfactant; b) water or a water-miscible hydrophilic organic solvent; and c) a microcapsule slurry or microcapsules as defined above, d) optionally non-encapsulated perfume.

According to a particular embodiment, the consumer product as defined above is in a powder form and comprises: a) from 2 to 65% by weight, relative to the total weight of the consumer product, of at least one surfactant; b) a microcapsule powder as defined above. c) optionally perfume powder that is different from the microcapsules defined above.

In the case of microcapsules including a perfume oil-based core, the products of the invention, can in particular be of used in perfumed consumer products such as product belonging to fine fragrance or “functional” perfumery. Functional perfumery includes in particular personal-care products including hair-care, body cleansing, skin care, hygiene-care as well as home-care products including laundry care, surface care and air care. Consequently, another object of the present invention consists of a perfumed consumer product comprising as a perfuming ingredient, the microcapsules defined above or a perfuming composition as defined above. The perfume element of said consumer product can be a combination of perfume microcapsules as defined above and free or non-encapsulated perfume, as well as other types of perfume microcapsules than those here-disclosed.

In particular a liquid consumer product comprising: a) from 2 to 65% by weight, relative to the total weight of the consumer product, of at least one surfactant; b) water or a water-miscible hydrophilic organic solvent; and c) a perfuming composition as defined above is another object of the invention.

Also a powder consumer product comprising

(a) from 2 to 65% by weight, relative to the total weight of the consumer product, of at least one surfactant; and

(b) a perfuming composition as defined above is part of the invention.

The invention’s microcapsules can therefore be added as such or as part of an invention’s perfuming composition in a perfumed consumer product.

For the sake of clarity, it has to be mentioned that, by “perfumed consumer product” it is meant a consumer product which is expected to deliver among different benefits a perfuming effect to the surface to which it is applied (e.g. skin, hair, textile, paper, or home surface) or in the air (air-freshener, deodorizer etc.). In other words, a perfumed consumer product according to the invention is a manufactured product which comprises a functional formulation also referred to as “base”, together with benefit agents, among which an effective amount of microcapsules according to the invention.

The nature and type of the other constituents of the perfumed consumer product do not warrant a more detailed description here, which in any case would not be exhaustive, the skilled person being able to select them on the basis of his general knowledge and according to the nature and the desired effect of said product. Base formulations of consumer products in which the microcapsules of the invention can be incorporated can be found in the abundant literature relative to such products. These formulations do not warrant a detailed description here which would in any case not be exhaustive. The person skilled in the art of formulating such consumer products is perfectly able to select the suitable components on the basis of his general knowledge and of the available literature.

Non-limiting examples of suitable perfumed consumer products can be a perfume, such as a fine perfume, a cologne, an after-shave lotion, a body-splash; a fabric care product, such as a liquid or solid detergent, tablets and unit dose (single or multi-chambers), a fabric softener, a dryer sheet, a fabric refresher, an ironing water, or a bleach; a personal-care product, such as a hair-care product (e.g. a shampoo, hair conditioner, a coloring preparation or a hair spray), a cosmetic preparation (e.g. a vanishing cream, body lotion or a deodorant or antiperspirant), or a skin-care product (e.g. a perfumed soap, shower or bath mousse, body wash, oil or gel, bath salts, or a hygiene product); an air care product, such as an air freshener or a “ready to use” powdered air freshener; or a home care product, such all-purpose cleaners, liquid or power or tablet dishwashing products, toilet cleaners or products for cleaning various surfaces, for example sprays & wipes intended for the treatment I refreshment of textiles or hard surfaces (floors, tiles, stone-floors etc.); a hygiene product such as sanitary napkins, diapers, toilet paper.

Another object of the invention is a consumer product comprising: a personal care active base, and - microcapsules or a microcapsule slurry as defined above or the perfuming composition as defined above, wherein the consumer product is in the form of a personal care composition.

Personal care active bases in which the microcapsules of the invention can be incorporated can be found in the abundant literature relative to such products. These formulations do not warrant a detailed description here which would in any case not be exhaustive. The person skilled in the art of formulating such consumer products is perfectly able to select the suitable components on the basis of his general knowledge and of the available literature.

The personal care composition is preferably chosen in the group consisting of a hair-care product (e.g. a shampoo, hair conditioner, a coloring preparation or a hair spray), a cosmetic preparation (e.g. a vanishing cream, body lotion or a deodorant or antiperspirant), or a skincare product (e.g. a perfumed soap, shower or bath mousse, body wash, oil or gel, bath salts, or a hygiene product);

Another object of the invention is a consumer product comprising: - a home care or a fabric care active base, and microcapsules or a microcapsule slurry as defined above or the perfuming composition as defined above, wherein the consumer product is in the form of a home care or a fabric care composition.

Home care or fabric care active bases in which the microcapsules of the invention can be incorporated can be found in the abundant literature relative to such products. These formulations do not warrant a detailed description here which would in any case not be exhaustive. The person skilled in the art of formulating such consumer products is perfectly able to select the suitable components on the basis of his general knowledge and of the available literature. Preferably, the consumer product comprises from 0.1 to 15 wt%, more preferably between 0.2 and 5 wt% of the microcapsules of the present invention, these percentages being defined by weight relative to the total weight of the consumer product. Of course the above concentrations may be adapted according to the benefit effect desired in each product.

An object of the invention is a consumer product, preferably a home care or a fabric care consumer product comprising the microcapsules or the microcapsule slurry as defined above, wherein the consumer product has a pH less than 7.

An object of the invention is a consumer product, preferably a home care or a fabric care consumer product comprising the microcapsules or the microcapsule slurry as defined above, wherein the consumer product has a pH equals or greater than 7.

For liquid consumer product mentioned below, by “active base”, it should be understood that the active base includes active materials (typically including surfactants) and water.

For solid consumer product mention below , by “active base”, it should be understood that the active base includes active materials (typically including surfactants) and auxiliary agents (such as bleaching agents, buffering agent; builders; soil release or soil suspension polymers; granulated enzyme particles, corrosion inhibitors, antifoaming, sud suppressing agents; dyes, fillers, and mixtures thereof).

Fabric softener

An object of the invention is a consumer product in the form of a fabric softener composition comprising: a fabric softener active base; preferably comprising at least one active material chosen in the group consisting of dialkyl quaternary ammonium salts, dialkyl ester quaternary ammonium salts (esterquats), Hamburg esterquat (HEQ), TEAQ (triethanolamine quat), silicones and mixtures thereof, the active base being used preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, a microcapsule slurry or microcapsules as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Liquid detergent

An object of the invention is a consumer product in the form of a liquid detergent composition comprising: a liquid detergent active base; preferably comprising at least one active material chosen in the group consisting of anionic surfactant such as alkylbenzenesulfonate (ABS), secondary alkyl sulfonate (SAS), primary alcohol sulfate (PAS), lauryl ether sulfate (LES), methyl ester sulfonate (MES) and nonionic surfactant such as alkyl amines, alkanolamide, fatty alcohol poly(ethylene glycol) ether, fatty alcohol ethoxylate (FAE), ethylene oxide (EO) and propylene oxide (PO) copolymers, amine oxydes, alkyl polyglucosides, alkyl polyglucosamides, the active base being used preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, a microcapsule slurry or microcapsules as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Solid detergent

An object of the invention is a consumer product in the form of a solid detergent composition comprising: a solid detergent active base; preferably comprising at least one active material chosen in the group consisting of anionic surfactant such as alkylbenzenesulfonate (ABS), secondary alkyl sulfonate (SAS), primary alcohol sulfate (PAS), lauryl ether sulfate (LES), methyl ester sulfonate (MES) and nonionic surfactant such as alkyl amines, alkanolamide, fatty alcohol poly(ethylene glycol) ether, fatty alcohol ethoxylate (FAE), ethylene oxide (EO) and propylene oxide (PO) copolymers, amine oxydes, alkyl polyglucosides, alkyl polyglucosamides, the active base being used preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, a microcapsule powder or microcapsule slurry or microcapsules as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Shampoo/shower gel

An object of the invention is a consumer product in the form of a shampoo or a shower gel composition comprising: a shampoo or a shower gel active base; preferably comprising at least one active material chosen in the group consisting of sodium alkylether sulfate, ammonium alkylether sulfates, alkylamphoacetate, cocamidopropyl betaine, cocamide MEA, alkylglucosides and aminoacid based surfactants and mixtures thereof, the active base being used preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, a microcapsule slurry or microcapsules as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Rinse-Off Conditioner

An object of the invention is a consumer product in the form of a rinse-off conditioner composition comprising: a rinse-off conditioner active base; preferably comprising at least one active material chosen in the group consisting of cetyltrimonium chloride, stearyl trimonium chloride, benzalkonium chloride, behentrimonium chloride and mixture thereof, the active base being used preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, a microcapsule slurry or microcapsules as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Solid scent booster

An object of the invention is a consumer product in the form of a solid scent booster composition comprising: a solid carrier, preferably chosen in the group consisting of urea, sodium chloride, sodium sulphate, sodium acetate, zeolite, sodium carbonate, sodium bicarbonate, clay, talc, calcium carbonate, magnesium sulfate, gypsum, calcium sulfate, magnesium oxide, zinc oxide, titanium dioxide, calcium chloride, potassium chloride, magnesium chloride, zinc chloride, saccharides such as sucrose, mono-, di-, and polysaccharides and derivatives such as starch, cellulose, methyl cellulose, ethyl cellulose, propyl cellulose, polyols/sugar alcohols such as sorbitol, maltitol, xylitol, erythritol, and isomalt, PEG, PVP, citric acid or any water soluble solid acid, fatty alcohols or fatty acids and mixtures thereof, a microcapsule slurry or microcapsules as defined above, in a powdered form, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil. Liquid scent booster

An object of the invention is a consumer product in the form of a liquid scent booster composition comprising: an aqueous phase, a surfactant system essentially consisting of one or more than one non-ionic surfactant, wherein the surfactant system has a mean HLB between 10 and 14, preferably chosen in the group consisting of ethoxylated aliphatic alcohols, POE/PPG (polyoxyethylene and polyoxypropylene) ethers, mono and polyglyceryl esters, sucrose ester compounds, polyoxyethylene hydroxylesters, alkyl polyglucosides, amine oxides and combinations thereof; a linker chosen in the group consisting of alcohols, salts and esters of carboxylic acids, salts and esters of hydroxyl carboxylic acids, fatty acids, fatty acid salts, glycerol fatty acids, surfactant having an HLB less than 10 and mixtures thereof, and a microcapsule slurry or microcapsules as defined above, in the form of a slurry, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil.

Hair coloration

An object of the invention is a consumer product in the form of an oxidative hair coloring composition comprising: an oxidizing phase comprising an oxidizing agent and an alkaline phase comprising an alkakine agent, a dye precursor and a coupling compound; wherein said dye precursor and said coupling compound form an oxidative hair dye in the presence of the oxidizing agent, preferably in an amount comprised between 85 and 99.95% by weight based on the total weight of the composition, microcapsules or a microcapsule slurry as defined above, preferably in an amount comprised between 0.05 to 15 wt%, more preferably between 0.1 and 5 wt% by weight based on the total weight of the composition, optionally free perfume oil

Perfuming composition According to a particular embodiment, the consumer product is in the form of a perfuming composition comprising:

0.1 to 30%, preferably 0.1 to 20% of microcapsules or a microcapsule slurry as defined previously,

0 to 40%, preferably 3-40% of perfume, and

- 20-90%, preferably 40-90% of ethanol, by weight based on the total weight of the perfuming composition.

The invention will now be further described by way of examples. It will be appreciated that the invention as claimed is not intended to be limited in any way by these examples.

Example 1

Preparation of soluble Moringa seed protein extract

De-oiled Moringa seed powder was obtained from Lifetime Tea (Chandler, AZ, USA). The protein content is 52% by weight determined by nitrogen measurement with a factor of 6.25 (assuming proteins have nitrogen content of 16%). Soluble Moringa seed extract was prepared following the below protocol.

1. Add de-oiled Moringa seed powder of at least 50 grams to D.l. water with 1 kg batch size.

2. Mix the solution using a Silverson L4RT homogenizer at 7000 rpm for 20 min

3. Hold the protein solution in water batch at 60 °C for 20 min

4. Re-mixing the solution using at 7000 rpm for 5 min

5. Centrifuge the samples at 8000 rpm for 10 min

6. The supernatant is collected

7. The collected supernatant is freeze dried to obtain soluble moringa protein powders.

Example 2

Preparation of microcapsules A according to the invention

Freeze dried moringa seed extract was prepared at 10% extraction solids according to the protocol described in example 1. Limonene capsules were prepared following below steps.

1 . Reconstitute freeze dried moringa protein extract at 10%.

2. Dilute the reconstituted solution to 4% to obtain a clear solution. 3. Mix 13.5 g 4% dilution from step 2 with 3.2 g limonene in a glass jar using a stir bar for 20 min. An emulsion is formed.

4. Dilute the emulsion with 8.1 g D.l. water.

5. Mix the diluted emulsion for 20 min

6. Add transglutaminase (Activa Tl® origin: Ajinomoto) (ratio of enzyme to protein 1 : 100) to the diluted emulsion and mix for overnight.

7. Heat the mixture to 85 °C for 15 min to deactivate the enzyme. Cool the sample to room temperature. Coacervates was found to deposit onto limonene droplets as shown in Figure 1.

Example 3

Preparation of microcapsules B according to the invention

Freeze dried moringa protein extract was prepared at 10% extraction solids. Limonene capsules were prepared following below steps.

1 . Reconstitute freeze dried moringa protein extract at 5%.

2. Dilute 10 g 5% solution from step 1 to 2.5% with D.l. water.

3. Mix the 2.5% dilution from step 2 with 3 g limonene in a glass jar using a stir bar for 20 min to form an emulsion.

4. Mix the emulsion for 20 min

5. Add transglutaminase (ratio of enzyme to protein 1 :100) to the diluted emulsion and mix for overnight.

6. Heat the mixture to 85 °C for 15 min to deactivate the enzyme. Cool the sample to room temperature. Coacervates was found to deposit onto limonene droplets as shown in Figure 2 (microcapsules B).

Example 4

Preparation of microcapsules C according to the invention

Freeze dried moringa protein extract was prepared at 25% extraction solids. Limonene microcapsules were prepared following below steps.

1 . Reconstitute freeze dried moringa protein extract at 20%.

2. Dilute the 20% solution to varying concentrations (10%, 8%, 5%, 3%, 2%) with D.l. water. 3. Mix 90 g the diluted solution from step 2 with 10 limonene in a glass jar. Mix them at 5000 - 7000 rpm using a bench bio-homogenizer for 5 min.

4. Add transglutaminase (ratio of enzyme to protein 1 :3) to the diluted emulsion and mix for overnight.

5. Heat the mixture to 85 °C for 15 min to deactivate the enzyme. Cool the sample to room temperature. Coacervates was found to deposit at limonene interface as shown in Figure 3a (3% moringa protein extract - Microcapsules C1) and Figure 3b (10% moringa protein extract - Microcapsules C2).

Example 5

Preparation of moringa protein - gum Arabic coacervates

Mixture of moringa protein extract and gum Arabic was evaluated. To prepare the mixture solution, stock solutions of 10% gum Arabic and 20% moringa protein extract (freeze dried moringa protein extract made at 20% extraction solids was reconstituted at 20% solution) were made. Mixture solutions were made at 5% total solid content and the mass ratio of gum Arabic to Moringa protein extract was varied at 0.5, 0.75, 1.0, 1.25, and 1.5. One mixture is also made with total solid content of 7% and the ratio of gum Arabic to Moringa protein extract was 1.0. It was found that coacervates were formed in all these mixture solutions.

Limonene microcapsules stabilized by moringa protein extract-gum Arabic coacervates were prepared following the below steps.

1. Add 10 grams of limonene to 90 grams moringa protein-gum Arabic coacervate solution with total solid content of 5% and ratio of gum Arabic to moringa protein extract of 0.75.

2. Mix them at 3000 - 5000 rpm using a bench bio-homogenizer for 5 min.

3. Add transglutaminase (Activa Tl® origin: Ajinomoto) (ratio of enzyme to protein 1 :100) to the batch and mix at 45 °C for 3 hours.

4. Heat the mixture to 85 °C for 15 min to deactivate the enzyme. Cool the sample to room temperature.

Microscopic images shows that moringa protein-gum arabic coacervates were deposited on limonene oil droplets and rough surface can be observed from the prepared microcapsules.

Example 6 Preparation of morinqa protein - canola protein coacervates

Mixture of moringa protein extract and canola protein (CanolaPRO®, DSM-Firmenich,) was evaluated. To prepare the mixture solution, stock solutions of 5% canola protein (pH = 7.9 adjusted with sodium hydroxide solution) and 20% moringa protein extract (freeze dried moringa protein extract made at 20% extraction solids was reconstituted at 20% solution) were made. Mixture solution was made at 3% total solid content and the mass ratio of canola protein to Moringa protein extract at 1.0.

Limonene microcapsules stabilized by moringa protein extract-canola protein coacervates were prepared following the below steps.

1. Add 10 grams of limonene to 90 grams moringa protein-canola protein coacervate solution with total solid content of 3% and ratio of canola protein to moringa protein extract of 1.0.

2. Mix them at 3000 - 5000 rpm using a bench bio-homogenizer for 5 min.

It was clear that protein coacervates were deposited on limonene oil droplets as shown in Figure 4. It appears that the coacervates aggregated at the surface and formed thick interfacial layer which may help improve microcapsule stability.

Example 7

Preparation of moringa protein - pectin coacervates

Mixture of moringa protein extract and pectin (GENU® beta pectin, CP Kelco) was evaluated. To prepare the mixture solution, stock solutions of 2% pectin and 20% moringa protein extract (freeze dried moringa protein extract made at 20% extraction solids was reconstituted at 20% solution) were made. Mixture solution was made at 3% total solid content and the mass ratio of pectin to Moringa protein extract at 0.25.

Limonene microcapsules stabilized by moringa protein extract-pectin coacervates were prepared following the below steps. 1 . Add 10 grams of limonene to 90 grams moringa protein-pectin coacervate solution with total solid content of 3% and ratio of pectin to moringa protein extract of 0.25.

2. Mix them at 3000 - 5000 rpm using a bench bio-homogenizer for 5 min.

Coacervates were observed at the droplet interface as shown in Figure 5.

Example 8

Preparation of polyurea-based microcapsules according to the invention

Polyurea microcapsules (D to I) were prepared following this general procedure:

A 10 wt% or 20 wt% Moringa seed extract solution was prepared and optionally the undissolved solids were removed by centrifugation (8000 rpm, 20 min). The supernatant was then diluted to the desired final Moringa concentration to form coacervates (dilute to 5%). The oil phase (perfume oil A - see Table 1) containing Takenate D-110 N (75% ethyl acetate solution of Trimethylol propane-adduct of xylylene diisocyanate, origin: Mitsui Chemicals, Inc., Japan) - 2.0 or 2.5% based on the oil phase) was added to the Moringa coacervate solution and homogenized with an I KA Ultra Turrax T25 (18G) for 2 min at 7,000 rpm. The emulsion was transferred to a reactor and stirred with an overhead anchor stirrer. The emulsion was heated to 45°C and transglutaminase was added (Activa Tl). The emulsion was stirred for 3 hr at 45 °C (pH maintained at 5.0-5.3 w/ 10% NaOH). The slurry was then heated to 85 °C and stirred for 30 min before being cooled to RT. Microcapsules were obtained (see figure 6

- Microcapsules D)

Polyurea microcapsules (J) were prepared as follows:

A 10 wt% Moringa seed extract solution was prepared and the undissolved solids were removed by centrifugation (8000 rpm, 20 min). The supernatant was then diluted to the desired final Moringa concentration to form coacervates (dilute to 5%). The oil phase (perfume oil A - see Table 1) containing Takenate D-110 N (2.0% based on the oil phase) was added to the Moringa coacervate solution and homogenized with an I KA Ultra Turrax T25 (18G) for 2 min at 7,000 rpm. The emulsion was transferred to a reactor and stirred with an overhead anchor stirrer. The emulsion was heated to 45°C and stirred for 3 hr (pH maintained at 5.0- 5.3 w/ 10% NaOH). The slurry was then heated to 85 °C and stirred for 30 min before being cooled to RT. The pH was then adjusted to 4.45 and a glutaraldehyde solution (1 wt%) was added and stirred for 10 hr at RT. Table 1 : Perfume composition

Table 2: Microcapsule composition

Example 9

Performance of microcapsules according to the invention

A sufficient amount of exemplified microcapsules is weighed and mixed in a liquid detergent composition and in a fabric softener composition to add the equivalent of 0.2% perfume.

The concentrated liquid detergent base was the commercially available Tide® Free&Gentle (trademark of Procter and Gamble, USA).

The fabric softener composition is given below:

Table 3: Fabric softener composition

Protocol: Weigh 2g of sample (base with capsules) in a 20mL vial. Add to the vial 10 mL of the extraction solvent isooctane containing the internal standard 1 ,4-dibromobenzene at a precisely known concentration around 90 ng/uL. Shake for 45 min at 40RPM to extract the free perfume. Remove the solvent phase.

To measure the leakage in the base the Agilent GCFID7890A is used, the injector is set at 250°C, helium is used as the carrier gas at a flow rate of 1 mL/min, the oven temperature is programmed from 120°C, held 5 minutes, increased to 170°C at 10°C/min, increased to 220°C at 25°C/min and then increased to 260 at 25°C/min. To finish a post run is apply at 260°C to finish the measure.

Calibration solutions are prepared at 100, 300 and 600 ng/uL of fragrance oil in the isooctane. It is important that the fragrance oil used to prepare the calibration curve comes from the same batch used to produce the microcapsules. Table 4: Stability results

NM : Not measured

These results underline that the microcapsules of the present invention are stable in surfactant-based consumer products.

Example 10

Preparation of polyurea-based microcapsules according to the invention

Polyurea microcapsules (K to N) were prepared following this general procedure:

A 15 wt% or 20 wt% Moringa seed extract solution was prepared and the undissolved solids were optionally removed by centrifugation (8000 rpm, 15 min). The supernatant was then mixed with another biopolymer solution with pre-dissolved gum arabic (2.9 wt%) or predissolved Canola protein (3 wt%) to form coacervates (5 wt%, ratio of Moringa seed extract to another biopolymer = 1 : 1). The oil phase (perfume oil A - see Table 1 herein-above) containing Takenate D-110 N (75% ethyl acetate solution of Trimethylol propane-adduct of xylylene diisocyanate, origin: Mitsui Chemicals, Inc., Japan) - 1.0 or 2.0 wt% based on the oil phase) was added to the Moringa coacervate solution and homogenized with an I KA Ultra Turrax T25 (18G) for 2 min at 7,000 rpm. The emulsion was transferred to a reactor and stirred with an overhead anchor stirrer. The emulsion was heated to 45°C and transglutaminase was added (Activa Tl). The emulsion was stirred for 3 hr at 45 °C. The slurry was then heated to 85 °C and stirred for 30 min before being cooled to RT. Microcapsules were obtained (see figure 7 to 10 for respectively Microcapsules K to N)

Table 5: Microcapsule composition

Stability of prepared microcapsules in softener was evaluated during storage for 3 days at 37 °C . The results were shown in below Table 6. The test protocol is identical to Example 9 herein-above.

Table 6: Stability results

Example 11

Powder detergent composition

A sufficient amount of exemplified microcapsules is weighed and mixed in a powder detergent composition to add the equivalent of 0.2% perfume. Table 7: Powder detergent composition

Example 12

Liquid detergent composition

Microcapsules of the present invention are dispersed in a liquid detergent base described below to obtain a concentration of encapsulated perfume oil at 0.22%.

Table 8: Liquid detergent composition

1) Hostapur® SAS 60; Origin: Clariant

2) Edenor® K 12-18; Origin: Cognis

3) Genapol® LA 070; Origin: Clariant

4) Aculyn® 88; Origin: Dow Chemical

Example 13

Rinse-off conditioner Microcapsules of the present invention are dispersed in a rinse-off conditioner base described below to obtain a concentration of encapsulated perfume oil at 0.5%.

Table 9: Rinse-off conditioner composition

1) Genamin KDM P, Clariant 2) Tylose H10 Y G4, Shin Etsu

3) Lanette O, BASF

4) Arlacel 165-FP-MBAL-PA-(RB), Croda

5) Incroquat Behenyl TMS-50-MBAL-PA-(MH) HA4112, Croda 6) SP Brij S20 MBAL-PA(RB), Croda

7) Xiameter DC MEM-0949 Emulsion, Dow Corning

8) Alfa Aesar

Example 14

Shampoo composition

Microcapsules of the present invention are weighed and mixed in a shampoo composition to add the equivalent of 0.2% perfume.

Table 10: Shampoo composition

2) Schweizerhall

3) Glydant, Lonza

4) Texapon NSO IS, Cognis

5) Tego Betain F 50, Evonik

6) Amphotensid GB 2009, Zschimmer & Schwarz

7) Monomuls 90 L-12, Gruenau

8) Nipagin Monosodium, NIPA

Example 15

Antiperspirant roll-on emulsion composition

Microcapsules of the present invention are weighed and mixed in antiperspirant roll-on emulsion composition to add the equivalent of 0.2% perfume.

Table 11 : Antiperspirant roll-on emulsion composition

1) BRU 72; origin : ICI

2) BRU 721; origin : ICI

3) ARLAMOL E; origin : UNIQEMA-CRODA

4) LOCRON L; origin : CLARIAN Part A and B are heated separately to 75°C; Part A is added to Part B under stirring and the mixture is homogenized for 10 min. Then, the mixture is cooled under stirring; and Part C is slowly added when the mixture reached 45°C and Part D when the mixture reached at 35 °C while stirring. Then the mixture is cooled to room temperature. Example 16

Deodorant spray composition

Table 12: Deodorant spray composition

1) Irgasan® DP 300; trademark and origin : BASF

All the ingredients according to the sequence of Table 12 are mixed and dissolved. Then the aerosol cans are filled, crimp and the propellant is added (Aerosol filling: 40% active solution 60% Propane / Butane 2.5 bar).

Example 17

Shower-gel composition

Microcapsules of the present invention are weighed and mixed in the following composition to add the equivalent of 0.2% perfume.

Table 13: Shower gel composition

1) EDETA B POWDER; trademark and origin: BASF

2) CARBOPOL AQUA SF-1 POLYMER; trademark and origin: NOVEON

3) ZETESOL AO 328 U; trademark and origin: ZSCHIMMER & SCHWARZ

4) TEGO-BETAIN F 50; trademark and origin: GOLDSCHMIDT 5) KATHON CG; trademark and origin: ROHM & HASS

Example 18

Unit dose formulation

A sufficient amount of exemplified microcapsules is weighed and mixed in a unit dose formulation to add the equivalent of 0.2% perfume.

The unit dose formulation can be contained in a PVOH (polyvinyl alcohol) film. Table 14: Unit dose composition

Example 19 Soap bar

A sufficient amount of exemplified microcapsules is weighed and mixed in a soap bar formulation a concentration of 7.5% w/w.

Table 15: composition of soap formulation

Example 20

Cosmetic day cream

A sufficient amount of exemplified microcapsules is weighed and mixed into a cosmetic skin cream (see composition below) at a concentration of 5%w/w.

Table 16: Cream composition

1) ARLATONE 985 2) TEFOSE 2561

3) COSBIOL

4) GLYDANT PLUS

Example 21

Toothpaste formulation A sufficient amount of a microcapsule slurry M (prepared according to the protocol disclosed in example 1 except that a menthol flavor is encapsulated) is weighed and mixed in the following composition to add the equivalent of 0.2% flavor. Table 17: Toothpaste formulation

1) Tixosil 73; trademark and origin :

2) Tixosil 43; trademark and origin :

Claims

CLAIMS - A coacervate core-shell microcapsule comprising a hydrophobic material, preferably a flavor or a perfume, wherein: a) the hydrophobic material is encapsulated in the core of the coacervate coreshell microcapsule, and b) the shell of the coacervate core-shell microcapsule comprises at least one Moringa oleifera extract, and wherein the shell is cross-linked. - The microcapsule according to claim 1 , wherein the Moringa oleifera extract is a Moringa oleifera seed extract. - The microcapsule according to claim 1 or 2, wherein the Moringa oleifera extract is in an extract from Moringa oleifera seed flour, preferably de-oiled Moringa oleifera seed flour. - The microcapsule according to anyone of the preceding claims, wherein the content of protein in the Moringa oleifera extract is comprised between 30% and 90%, preferably between 40% and 80% by weight based on the total weight of the extract. - The microcapsule according to anyone of the preceding claims, wherein the Moringa oleifera extract is present in an amount comprised between 0.1% and 30%, preferably between 1% and 15% based on the total weight of the microcapsule. - The microcapsule according to anyone of the preceding claims, wherein the shell comprises a non-protein polymer and/or a protein polymer. - The microcapsule according to anyone of the preceding claims, wherein the shell of the microcapsule is cross-linked using formaldehyde, genipin, tannins, acetaldehyde, glutaraldehyde, glyoxal, chrome alum, transglutaminase and mixtures thereof. - The microcapsule according to any one of the preceding claims, wherein the shell comprises an additional polymeric material. 9- The microcapsule according to claim 8, wherein the polymeric material is chosen in the group consisting of polyurea, polyurethane, polyamide, polyester, polyacrylate, polysiloxane, polycarbonate, polysulfonamide, polymers of urea and formaldehyde, melamine and formaldehyde, melamine and urea, or melamine and glyoxal and mixtures thereof.

10- The microcapsule according to claims 8 or 9, wherein the polymeric material is used in an amount comprised between 0.5 and 20% based on the total weight of the microcapsule.

11- A process for preparing the coacervate core-shell microcapsule as defined in anyone of the preceding claims, wherein the process comprises the steps of: a) preparing a solution by dissolving at least one Moringa oleifera extract in aqueous solution, preferably water; b) optionally, preparing a solution by dissolving at least one non-protein polymer and/or at least one protein polymer in aqueous solution, preferably water; c) optionally, mixing the prepared solutions comprising at least one plant protein extract and at least one non-protein polymer and/or at least one protein polymer; d) preparing, an emulsion and/or suspension by emulsifying and/or suspending a hydrophobic material and optionally a polyfunctional monomer in the solution; e) forming a coavervate shell comprising the Moringa oleifera extract and optionally the non-protein polymer and/or the protein polymer around droplets and/or particles of the hydrophobic material present in an emulsion and/or suspension; and f) cross-linking the shell.

12- The process according to claim 11 , wherein step f) is carried out using a cross-linker in an amount comprised between 0.005 and 5%, preferably between 0.5 and 2% based on the total weight of the emulsion and/or suspension.

13- A consumer product comprising the coacervate core-shell microcapsule according to claim 1-10, wherein said product is a flavoured or fragranced product.

14- The consumer product according to claim 13, wherein the fragranced product is chosen in the group consisting of a liquid or solid detergent, a fabric softener, liquid or solid scent-boosters, a shampoo, a shower gel, a hair conditioning product, a deodorant or antiperspirant. - The consumer product according to claim 13, wherein the flavored product is chosen group consisting of a meat- and/or fish-based food or analogue, a stock, a savory cube, a powder mix, a beef or pork based product, a seafood, surimi, instant noodles, rice, soups, sauces, ready-made meal, frozen or chilled pizza, pasta, potato flakes or fried, noodles, a potato/tortilla chip, a microwave popcorn, nuts , a pretzel, a rice cake, a rice cracker, fermented dairy analogue beverage, acidified dairy analogue beverage, non- fermented dairy analogue beverage, cheese or cheese analogue, yoghurt or yoghurt analogue, nutritional supplement, nutritional bar, cereal, ice cream, dairy-free ice cream, confectionary product, chewing gum, hard-boiled candy and powdered drinks.